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Development And Validation Of Novel Transmitted/founder Shivs For Hiv-1 
Persistence And Cure Research 
Abstract 
A robust simian-human immunodeficiency virus (SHIV)-rhesus macaque (RM) model of HIV latency and 
cure is needed. Our group has generated >20 SHIVs encoding various HIV-1 Envs of interest, including 
transmitted/founder (TF) Envs. TF SHIVs encode a substitution at Env residue 375 that confers 
consistent early viral kinetics in RM, although longitudinal kinetics are more variable. Further, TF SHIVs 
have not been evaluated for their suitability for HIV latency and cure research. For my first aim, I evaluated 
two promising TF SHIVs, SHIV.191859 and SHIV.CH848, for their viral kinetics and persistence during 
suppressive combination antiretroviral therapy (cART). These SHIVs demonstrated consistent early viral 
kinetics, rapid viremic suppression following cART initiation, and viral rebound following treatment 
interruption, mirroring HIV infection. Reservoir analyses of both peripheral and lymphoid cells revealed 
systemic virus dissemination and establishment of viral reservoirs that persisted despite cART. The viral 
dynamics and reservoir biology of SHIV.191859, and to a lesser extent SHIV.CH848, suggest that these TF 
SHIVs are promising reagents for a SHIV model of HIV latency and cure. For my second aim, I endeavored 
to engineer an enhanced clone of SHIV.CH505, a TF SHIV that is of significant interest to the HIV field but 
replicates variably over time in RM. A common signature of mutations that arose in 10 
SHIV.CH505-infected RM with high VLs was identified via single genome sequencing. To assess the 
contribution of signature mutations to viral fitness in vitro, a library of clones containing signature 
mutations alone or in combination was generated; these clones demonstrated modestly enhanced 
replication in isolation and significantly enhanced replication in combination compared to the parental 
(TF) virus. 8 combination clones that exhibited desirable characteristics in vitro were tested in vivo. A 
clone containing 5 mutations compared to the TF, 5MA, dramatically outcompeted all other viruses, 
including the TF, when tested in vivo in 7 RM. TZM-bl neutralization assays revealed that 5MA retained a 
native Env conformation. Further, 5MA demonstrated significantly enhanced entry into target cells 
compared to the TF. We have generated a minimally adapted SHIV.CH505 with enhanced replication that 
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DEVELOPMENT AND VALIDATION OF NOVEL TRANSMITTED/FOUNDER SHIVS 
FOR HIV PERSISTENCE AND CURE RESEARCH  
Anya Bauer 
Katharine Bar  
 
A robust simian-human immunodeficiency virus (SHIV)-rhesus macaque (RM) 
model of HIV latency and cure is needed. Our group has generated >20 SHIVs encoding 
various HIV-1 Envs of interest, including transmitted/founder (TF) Envs. TF SHIVs 
encode a substitution at Env residue 375 that confers consistent early viral kinetics in 
RM, although longitudinal kinetics are more variable. Further, TF SHIVs have not been 
evaluated for their suitability for HIV latency and cure research. For my first aim, I 
evaluated two promising TF SHIVs, SHIV.191859 and SHIV.CH848, for their viral 
kinetics and persistence during suppressive combination antiretroviral therapy (cART). 
These SHIVs demonstrated consistent early viral kinetics, rapid viremic suppression 
following cART initiation, and viral rebound following treatment interruption, mirroring 
HIV infection. Reservoir analyses of both peripheral and lymphoid cells revealed 
systemic virus dissemination and establishment of viral reservoirs that persisted despite 
cART. The viral dynamics and reservoir biology of SHIV.191859, and to a lesser extent 
SHIV.CH848, suggest that these TF SHIVs are promising reagents for a SHIV model of 
HIV latency and cure. For my second aim, I endeavored to engineer an enhanced clone 
of SHIV.CH505, a TF SHIV that is of significant interest to the HIV field but replicates 
variably over time in RM. A common signature of mutations that arose in 10 
SHIV.CH505-infected RM with high VLs was identified via single genome sequencing. 
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To assess the contribution of signature mutations to viral fitness in vitro, a library of 
clones containing signature mutations alone or in combination was generated; these 
clones demonstrated modestly enhanced replication in isolation and significantly 
enhanced replication in combination compared to the parental (TF) virus. 8 combination 
clones that exhibited desirable characteristics in vitro were tested in vivo. A clone 
containing 5 mutations compared to the TF, 5MA, dramatically outcompeted all other 
viruses, including the TF, when tested in vivo in 7 RM. TZM-bl neutralization assays 
revealed that 5MA retained a native Env conformation. Further, 5MA demonstrated 
significantly enhanced entry into target cells compared to the TF. We have generated a 
minimally adapted SHIV.CH505 with enhanced replication that has broad applications 
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CHAPTER 1: INTRODUCTION 
Origins of HIV-1  
             Acquired immunodeficiency syndrome (AIDS) was first described in CDC’s 
Morbidity and Mortality Weekly Report in 1981: young, recently healthy men were dying 
of opportunistic infections and unusual cancers due to an unknown cause1. A mere 2 
years later, Françoise Barré-Sinoussi, Luc Montagnier and colleagues isolated what 
would become known as the human immunodeficiency virus (HIV) and identified it as the 
causative agent of AIDS2,3. HIV/AIDS would go on to become one of the defining public 
health crises of the late 20th century, with over 77 million infections and over 35 million 
AIDS-related deaths reported as of 20184. HIV-1 group M, which is the most pathogenic 
subtype and is responsible for the majority of the global pandemic, began replicating in 
humans in approximately 1931,5 following cross-species transmission from a simian-
immunodeficiency virus (SIV)-infected chimpanzee6. There have been 3 further cross-
species transmissions from chimpanzees and gorillas, resulting in 3 additional  
genetically distinct HIV-1 groups: N, O, and P7. HIV-2, which is less pathogenic and is 
more geographically restricted to West Africa8, originated from a SIV-infected sooty 
mangabey9.   
 
The biology of HIV-1 infection  
HIV-1 is a member of the Lentivirus genus in the Retroviridae family3; viruses in 
this genus are characterized by long incubation periods leading to progressive 
illnesses10. HIV-1 is a single-stranded, positive sense, enveloped RNA virus, with a 
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genome that is ~9.8 kB in length. The HIV-1 genome consists of 9 open reading frames 
that code for 15 proteins. Gag, Pol, and Env are the 3 main proteins produced during 
early viral transcription10. Env, which is the sole protein expressed on the surface of the 
virion, mediates entry into target cells and fusion of the viral and host cell membranes. 
Gag mediates a number of virion assembly and maturation processes, including 
synthesis of the viral capsid, which houses 2 copies of the HIV-1 RNA genome10. The 
cleavage of the Pol precursor by the viral enzyme protease results in the formation of 3 
enzymes that are critical for infection of the host cell: reverse transcriptase, which is 
used to transcribe the HIV-1 genome after fusion and entry, protease, and integrase, 
which enables integration of the HIV-1 provirus into the host cell genome. 
2 regulatory proteins play important roles for viral replication: Tat, which activates 
viral gene transcription and Rev, which plays a crucial role in nuclear export of viral RNA 
to the cytoplasm and is essential for regulating viral protein expression11. 4 additional 
proteins, Vpu, Vpr, Vif, and Nef, are accessory proteins that aid in viral immune evasion 
and/or mediate proper virus assembly and export10.  
Env is synthesized as a 160 kD protein that is then cleaved by Furin, a host-
derived protease, to form the gp120 Env ectodomain and the gp41 
transmembrane/endomain12. Following cleavage of gp160 Env, the gp41 and gp120 
subunits become non-covalently associated, forming an Env trimer consisting of 3 gp120 
and 3 gp41 domains12. Upon binding to the host receptor CD4, which is expressed on 
CD4+ T cells as well as other immune cells, including macrophages13, Env undergoes a 
conformational change to initiate fusion with the host membrane12. Following CD4 
binding, Env is able to bind to the host co-receptor, CCR5 or CXCR4, which triggers a 
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second conformational change, enabling fusion of the virus and host cell membranes 
and injection of the viral genome into the host cytoplasm12. After entry into the target cell 
is complete, the RNA genome located in the viral capsid protein, p24, is uncoated and 
reverse-transcribed by reverse transcriptase10. The resultant full-length viral double-
stranded DNA, now called a provirus, is integrated into the host chromosome by 
integrase, which enables the cell to remain infected for the duration of its lifetime10. 
 
HIV-1 transmission and viral kinetics 
            HIV is transmissible via sexual, perinatal, and parenteral routes; in adults, HIV-1 
is predominantly acquired sexually14.  A study of over 100 donor-host transmission pairs 
found that in ~80% of heterosexual individuals and 60% of men who have sex with men 
(MSM), infection is initiated by a single virus15. This finding implies that there is a low 
multiplicity of infection based on the assumption that there is limited and random 
diversification in the recipient during acute infection as a direct result of a stringent 
genetic bottleneck during transmission15.  Factors influencing the selection of the 
transmitted/founder, or TF virus in the recipient are not completely understood, but 
include preferential tropism for the CCR5 viral co-receptor and modestly enriched Env 
content16. A recent report identified a signature of interferon-beta resistance in 
transmitted/founder isolates17. 
         Following transmission, HIV-1 rapidly disseminates throughout the body, leading to 
the saturation of target CD4+ cells in the peripheral blood and infection of CD4+ cells in 
various lymphoid tissues, leading to peak viral loads (VL) of 106 – 108 copies/ml, or 
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c/ml18. The VL in most people living with HIV (PLWH) decreases to 102 – 105 c/ml 
following the exhaustion of activated target cells during peak infection and the onset of 
adaptive immune responses such as CD8 T cells and antibodies18; this decreased post-
peak VL is known as the viral set point.  If combination antiretroviral therapy (cART) is 
not initiated, PLWH will develop significant CD4 T cell depletion and succumb to 
opportunistic AIDS-associated infections within a median of 10 years19. 
 
HIV-1 genetic diversity and epidemiology 
The virus population in PLWH rapidly undergoes diversification due to the error-
prone reverse-transcriptase, which has an error rate of approximately 3.7x10-4 
mutations/nucleotide20. This high error rate, in conjunction with the short half-life of an 
infected cell (~1 day)21,22 results in diversification of the virus population on the order of 
1% per year in PLWH15. As a result, HIV variants that that are resistant to host immune 
pressures, such as CD8 T cells23 and antibodies24,25 as well as antiviral agents26, can 
easily be selected for, leading to rapid and complete viral escape. As described earlier,  
innate immune responses have been shown to exert selective pressure on the virus 
population at the transmission stage17, while adaptive immune responses begin to exert 
significant selective pressure on the virus population as early as 1.5-4 weeks post-
infection (WPI) in PLWH27,28. The resultant within-patient diversity, which increases with 
each successive year of infection, has led to >5% interpatient diversity in pol29 and 25-
35% interpatient diversity in env across all HIV-1 isolates16. 
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HIV-1 group M disproportionately affects individuals in developing countries; the 
burden of disease is highest in sub-Saharan Africa4.  Group M is further subdivided into 
subtypes or clades based on genetic diversity. Subtype B viruses, which comprise ~10% 
of the global total, are found primarily in the Americas, Western Europe, and Australia30. 
Early HIV-1 research focused on subtype B viruses with near exclusivity, leading to a 
relative dearth of information on other HIV-1 subtypes until fairly recently despite their 
increased prevalence; this issue was compounded by the fact that countries with 
predominantly clade B infections had earlier access to cART31. Subtype C viruses, which 
comprise 50% of the global total, are most commonly found in Eastern and Southern 
Africa31. Subtype D viruses comprise 2.5% of the global total and are endemic to 
Eastern Africa30. Infection with a subtype D virus is associated with faster disease 
progression and a relatively rapid viral co-receptor switch from CCR5 to CXCR4, which 
facilitates the infection and depletion of broader subsets of CD4-expressing T cells, 
including naïve T cells, and often emerges concomitant with progression to AIDS30,32. 
The relationship between subtype and rate of disease progression seems to be less 
clear in other subtypes31. Multiple studies suggest that efficiency of various transmission 
types (mother-to-child, intravenous, and sexual) are variable among HIV-1 clades31. 
Thus, the extensive diversity and associated variation in viral characteristics across HIV-
1 clades significantly complicate efforts to produce HIV-1 vaccines and therapeutics that 




HIV-1 latency and persistence  
In 1996, the introduction of combination anti-retroviral therapy (cART), which 
durably suppresses viremia to <400 c/ml and leads to immune cell preservation and 
reconstitution in most individuals led to a significant decline in morbidity and mortality in 
the HIV+ population33. The introduction of integrase inhibitors in 2007 led to a further 
increase in the percentage of PLWH who achieve sustained virologic suppression. cART 
containing an integrase inhibitor leads to an exponential decline in plasma viremia to 
less than 50 c/ml within 2 months of cART initiation in most individuals34, resulting in 
significantly decreased morbidity and mortality in the HIV+ population35. Common 
standard-of-care cART regimens prescribed to PLWH often include a combination of 2 
nucleotide reverse transcriptase inhibitors and an integrase inhibitor36, although other 
effective regimens are available. If cART-mediated viral suppression is durably 
maintained, CD4 T cell depletion and progression to AIDS can be prevented. As a result, 
in today’s era of effective cART, PLWH have a life expectancy that approaches that of 
the general population37. 
However, cART has several limitations: serious adverse effects, such as 
diabetes, kidney dysfunction, and accelerated cardiovascular disease, have been 
reported in a subset of patients on cART36.  Further, lifelong adherence is required to 
prevent progression to AIDS, as discontinuation of cART in the setting of an analytical 
treatment interruption, or ATI, leads to viremic rebound in 85% of individuals within 4 
weeks and almost all patients within 12 weeks post-ATI38,39.  This systemic rebound 
originates from the HIV-1 latent reservoir, which is comprised of a population of long-
lived infected cells in PBMC and lymphoid tissues that persist indefinitely40. Studies of 
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peripheral blood have suggested that low-level viremia (~1 c/ml) occurs throughout the 
course of cART administration and cannot be reduced by further cART intensification41. 
The viral variants contributing to low-level viremia on cART, however, do not show 
evidence of genetic diversification or acquisition of novel drug resistance mutations42, 
implying that they result from constant, low-level reactivation of infected cells.  
There are numerous methods available to assess the kinetics of viral decay in 
various reservoirs upon initiation of cART. As described earlier, cART initiation is 
associated with an exponential decrease in plasma virus, leading to an undetectable VL 
(<50 c/ml) in most patients within 2 months of cART initiation. This decrease in plasma 
VL is accompanied by modest (~1-2 log10) decreases in cell-associated viral DNA (ca-
DNA) and viral RNA (ca-RNA) measurements, which reflect, at minimum, the clearance 
of plasma virus, productively infected activated T cells with a short half-life (~2 days), 
resting CD4 T cells with unintegrated virus, and likely shorter-lived effector cells21,22.  Ca-
DNA remains readily detectable in PLWH despite long-term suppressive cART, 
indicating that the HIV-1 reservoir is relatively stable on cART and has a slow decay rate 
on the order of months to years39.  This stable or very slow decay rate reflects the 
maintenance of longer lived cellular reservoirs, such as resting memory CD4 T cells 
(Tcm), which have a half-life of months to years and are known to comprise a large 
portion of the latent reservoir, along with effector memory T cells (Tem)43,44.  Modeling 
studies suggest that more than 60 years of cART treatment alone would be required to 
achieve sustained viremic remission upon ATI, otherwise known as a “functional cure”40. 




The mechanisms that facilitate HIV-1 reservoir seeding and maintenance are not 
completely understood, underscoring the need for validated animal models to elucidate 
mechanisms of HIV-1 reservoir formation and persistence. Recent studies have 
identified one major contributor to reservoir homeostasis: clonal expansion45, or the 
continuous proliferation of Tcm and Tem that harbor HIV proviruses. Further, integration 
site and sequencing analyses have revealed that the viruses in these expanded clones 
have identical sequences as well as integration sites46, and thus are presumed to derive 
from a single latently infected cell. HIV-1 expanded clones have been shown to be 
extremely long-lived and proliferate due to several mechanisms, including antigen-driven 
expansion, homeostatic proliferation, and integration site-driven cellular proliferation46.   
Upon ATI, viruses originating from genetically distinct virus lineages begin 
replicating systemically in PLWH within the first week of rebound, indicating that 
numerous non-identical virus-infected cells reactivate to contribute to recrudescent 
viremia upon treatment interruption47–50.  Recrudescent viremia results from the 
reactivation of distinct cells in both blood and lymphoid tissue compartments, supporting 
a multifocal model of rebound50.  Further, current latency assays have not been able to 
predict which virus populations will contribute to recrudescent viremia upon ATI51, which 
can be considered a major barrier to developing effective HIV-1 cure strategies. 
 
The advent of broadly neutralizing antibodies (bNAbs) 
Env is the only viral protein that is able to be targeted by host, or autologous 
neutralizing antibody responses due its location on the surface of the virion12. Circulating 
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HIV-1 variants, however, have been adapted to effectively evade autologous antibody 
responses using several mechanisms, including conformational masking of key epitopes 
via N-linked glycosylation and extensive sequence variation in Env as described earlier, 
enabling rapid escape24. The sensitivity of Envs to autologous neutralizing antibody 
responses can generally be divided into several classes: Tier 1 Envs are unusually 
sensitive to autologous and heterologous, or non-host neutralizing antibody responses, 
Tier 2 Envs are more resistant, and Tier 3 Envs are most resistant52. Nearly all TF 
viruses exhibit Tier 2 and 3 neutralization resistance, thereby presenting an obstacle to 
development of both effective autologous antibody responses and vaccines52.  
 Recent scientific advances have identified bNAbs, or antibodies with potent and 
broad specificity against diverse HIV isolates, in a subset of chronically infected 
individuals53. Isolated bNAbs potently neutralized over 90% of viruses when tested in 
vitro against a panel broadly representative of global isolates53,54. When administered 
prophylactically, bNAbs were shown to confer protection against infection in a non-
human primate (NHP) model of HIV infection.55 Further, bNAbs, when administered in 
tandem with cART in multiple NHP studies, were shown to significantly delay viral 
rebound compared to a control group56,57. Next-generation vaccine design holds promise 
for the elicitation of bNAbs in humans, as studying Env-antibody coevolution in an HIV+ 
individual that has developed bNAbs could serve as a blueprint for the design of 
effective immunogens. BNAbs that have been identified thus far target various 
conserved epitopes on Env, including the CD4 binding site, the membrane-proximal 
external region, the trimer apex, and variable loop 3, which enables Env to bind the viral 
co-receptors CCR5 and CXCR453. 
10 
 
 Multiple studies assessing the efficacy of monoclonal bNAbs in suppressing 
viremia following ATI have demonstrated a significant delay in time to rebound in 
PLWH58,47. Trials assessing the efficacy of bNAbs in combination for this application are 
in process. On this basis, various clinical trials evaluating the efficacy of next-generation 
bNAbs for viral suppression in place of cART initiation and for HIV-1 prevention in 
newborns and constantly exposed individuals are ongoing59, underscoring the promise 
of this novel class of HIV-1 biologics. 
  
Non-human primate models of HIV infection: SIVmac  
NHP models for HIV-1 infection have played an integral role in understanding 
transmission, immunopathogenesis, and evaluating prophylactic and therapeutic 
interventions60. The Indian-origin rhesus macaque (RM) is the most commonly used 
NHP model, although cynomolgus macaques and Chinese-origin RM are also used in 
HIV-1 research60. Infection of Indian-origin RM with a macaque-adapted SIV (SIVmac) 
leads to viral kinetics and immunopathogenesis similar to HIV-1 infection. The clinical 
hallmarks of untreated HIV-1 infection, however, are greatly accelerated in the SIVmac 
model, as untreated animals typically progress to AIDS within ~1 year post infection.61 
This accelerated model of pathogenesis and disease progression makes SIVmac an 
attractive reagent for certain NHP studies.  
Many insights have been gained from studies of SIVmac-infected NHP, including 
the identification of memory CD4 T cells as the main viral target in peripheral blood and 
lymphoid tissues62 as well as identification of host factors that influence peak and set 
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point viremia63.  SIVmac-infected RM, however, typically require more than 4 months of 
cART administration to achieve durable virus suppression,60,64 in contrast to the 2 month 
timeframe needed for most PLWH receiving current standard-of-care cART regimens34.  
An additional difference between the SIVmac-NHP model and HIV-1 infection is 
that set point VL in infected animals average around 106 c/ml, which is 1-2 log10-fold 
higher than in HIV-1 infection65. This increased set point VL is likely attributable to some 
combination of more severe immune dysregulation, microbial translocation, chronic 
inflammation, and/or infection of cellular subsets in comparison to HIV-1 infection63.  
Further, there are important structural differences between SIVmac and HIV-1 Envs. The 
SIVmac239 and HXB2 Envs, which are considered to be representative of all SIVmac 
and HIV-1 isolates, respectively, are 50% divergent, thus limiting the translatability of 
studies that evaluate Env-targeting agents, such as vaccines and bNAbs66. Nonetheless, 
SIVmac is considered to be the most robust NHP model for HIV-1 infection by many 
investigators, as a plethora of well-powered studies show reproducible VL kinetics and 
associated immunopathogenesis in large cohorts of outbred RM. 
 
Non-human primate models of HIV infection: a brief history of SHIVs 
An alternative and widely used NHP model of HIV-1 infection is the chimeric 
simian-human immunodeficiency virus (SHIV)-macaque model. SHIVs encode an HIV-1 
envelope glycoprotein (Env) within the background of macaque-adapted simian 
immunodeficiency virus (SIVmac) structural and regulatory elements. SHIVs have wide-
ranging applications, including studies of HIV-1 reservoir biology and pathogenesis, and 
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are the most directly suitable NHP model for evaluating HIV-1 Env-targeting agents such 
as bNAbs67 and vaccines.   
The first SHIV, 89.6, was generated by Sodroski and colleagues in 199667. SHIV 
89.6 encodes a dual-tropic clade B Env. This virus was initially non-pathogenic in rhesus 
macaques; virus acquisition resulted in non-persistent infection as assessed by plasma 
VL, minimal CD4 T cell depletion, and lack of progression to AIDS. Serial passage, or 
transfer of blood and/or tissues from an infected animal to a naïve animal, resulted in a 
pathogenic viral swarm, termed 89.6P, after several sequential transfers. Serial passage 
is based upon the idea that virus adaptation will occur given enough time and enough 
exposures to various target hosts, leading to augmented virulence. 89.6P reliably elicited 
CD4 T cell depletion and progression to AIDS in infected RM. After 3 passages, a 
particularly virulent viral swarm, 89.6P3, was created, from which an infectious molecular 
clone, KB9, was isolated. Subsequent studies identified several changes in the Env 
amino acid (AA) sequence that were associated with the enhanced pathogenicity of 
89.6P3/KB9; a follow up report identified increased fusogenicity and affinity for CCR5 as 
the factors responsible for the increased virulence of KB968.  
Several issues, however, quickly emerged with the use of SHIV 89.6. First, the 
relentless CD4 T cell depletion in RM within weeks of inoculation, on account of the dual 
tropism of the 89.6 Env, diverged greatly from the disease course typical of HIV-1 
infection. In HIV-1 infection, co-receptor switch typically only occurs after years of 
infection and does not occur in all PLWH67,69. In addition, TF viruses are overwhelmingly 
CCR5-tropic15, limiting the extent to which SHIV 89.6 recapitulates HIV-1 infection in 
individuals who have not progressed to AIDS. Further, preclinical studies that evaluated 
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myriad vaccines, including DNA vaccines, peptides, proteins, inactivated virions, etc., 
yielded promising results in SHIV 89.6-infected RM but had severely discordant results 
in clinical trials; none of the vaccine candidates showed protection in humans70. SHIV 
89.6 has undoubtedly served as a prototype for subsequent SHIV design. 
In 2001, Cheng-Mayer and colleagues71 addressed the dual-tropism issue by 
generating a novel SHIV encoding an exclusively CCR5-tropic clade B Env, SF162, 
which was also derived from an AIDS patient. While this SHIV initially replicated sub-
optimally in RM similar to its predecessor, an analogous in vivo passage approach 
yielded a more pathogenic viral swarm, SHIV SF162P3, which was both intravenously 
and mucosally transmissible. The original Env encoded by this SHIV, however, was 
found to be unusually sensitive to neutralization by antibodies72. The antigenic profile 
and protein conformation of the SHIV 162P3 Env was recently described; it was found to 
be unusually neutralization resistant to a number of bNAbs such as 4E10 that 
neutralized all primary HIV-1 isolates tested73. Further, approximately 25-40% of RM 
infected with SHIV SF162P3 exhibited spontaneous control of viremia by 8 weeks post-
infection in the original report and in follow-up studies71,74; spontaneous control can be 
defined as suppression of plasma viremia to below 102-3 c/ml. 
In 2006, Ruprecht and colleagues generated the first clade C CCR5-tropic SHIV 
1157ipd3N475 in an effort to address the lack of SHIVs encoding non-clade B Envs. 
SHIV 1157ipd3N4 reproducibly infected RM after 3 passages. In addition, the group 
added an additional NF-kB binding site to the SHIV genome, leading to enhanced in vivo 
virulence due to increased LTR-driven viral gene expression. Like its predecessors, 
SHIV 1157ipd3N4 is mucosally and intravenously transmissible; early viral kinetics are 
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similar to HIV-1 infection. Despite all aforementioned modifications, set point viremia in 
SHIV 1157idp3N4-infected RM is highly variable: 54% of RM (n=13) in the original study 
spontaneously controlled viremia to below 103 c/ml by 28 WPI, 71% of which suppressed 
viremia to below the limit of assay quantification (50 c/ml). 
In 2010, a novel SHIV, AD8, was developed by Martin and colleagues76 with the 
goal of generating a more neutralization-resistant CCR5-tropic virus. Serial passage 
again led to the generation of a virulent viral swarm that resulted in CD4 T cell depletion 
and progression to AIDS in most RM76. This CCR5-tropic SHIV also exhibited variable 
persistence, as approximately 20% of RM infected with this virus spontaneously 
controlled viremia to <103 c/ml by 32 weeks post-infection76. An infectious molecular 
clone (IMC) isolated from the SHIV AD8 swarm, EO77, consistently elicited autologous 
neutralizing antibodies. Only 25-50% percent of RM infected with the original SHIV AD8 
swarm, however, produced potent autologous neutralizing antibodies (>50% 
neutralization compared to virus-only control) in multiple studies76,77. 
 In summary, these SHIVs and others have yielded important insights over the 
several decades that they have been in use. SHIVs have been used to study the biology 
of HIV-1 Env and its impact on virus-host interactions, transmission, and 
pathogenesis67,71,78,77 and have been particularly important in evaluating Env-targeting 
agents such as bNAbs56,57,79. 
Collectively, previous iterations of SHIVs have several limitations in their ability to 
reproduce key features of HIV-1 transmission and infection. The SHIVs described here 
do not accurately recapitulate key properties of transmitted/founder (TF) and primary 
HIV-1 isolates from early infection, such as CCR5 tropism15,80,81,67, infection and 
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depletion of relevant long-lived T cell subsets77,78, and induction of consistent autologous 
antibody responses24,82,3,4. Further, most SHIVs do not fully reflect the original antigenic 
conformation and neutralization sensitivity of native HIV-1 Env as a result of the serial 
passage experiments that are necessary for productive infection of RM1,2,3,4. A small 
number of SHIVs encoding primary or TF Envs have been shown to fortuitously confer 
high peak and set point viremia in RM without adaptation; none of these SHIVs, 
however, have been extensively characterized with regard to their antigenic 
conformation or assessed for persistence in the presence of antiretrovirals83. In addition, 
the mechanisms responsible for variable SHIV persistence and spontaneous control of 
CCR5-tropic SHIVs in RM, as exhibited by SHIVs 162P3 and AD8, are as of yet 
unknown. 
 
A new generation of SHIVs 
Recently, our group reported the development of a novel strategy to generate 
designer SHIVs encoding native TF or primary Envs with Tier 2 neutralization sensitivity, 
henceforth referred to as TF SHIVs84. Residue 375, which is located in the CD4 binding 
site pocket of Env, was found to be under strong selection pressure across all primate 
lentiviruses. In HIV isolates, the preferred residue at this position is serine, while in 
SIVmac isolates, the preferred residue is bulky and hydrophobic (i.e. tryptophan, 
tyrosine, histidine). Making a single amino acid substitution at Env position 375 mediated 
increased affinity of HIV-1 Env for rhesus CD4. Env 375 substitution enables effective in 
vitro and in vivo infection of RM while preserving the antigenic conformation and 
neutralization sensitivity of the parental Env.   
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TF SHIVs consistently confer productive infection, high peak viremia, and 
desirable early viral kinetics when administered via mucosal or intravenous routes as 
described in 84,85,86.  Importantly, TF SHIVs are CCR5-tropic and have been shown to 
reproducibly induce autologous antibody responses in infected RM, thereby 
recapitulating key qualities of primary and TF HIV-1 isolates87. Further, the 20+ TF 
SHIVs generated to date encode epidemiologically important Envs from clades that have 
been underrepresented in previous iterations of SHIVs, including A, AE, C, and D, 
among others84. Importantly, the ability to encode any Env of interest in TF SHIVs using 
this novel approach presents a heretofore unrealized opportunity for the development of 
a broadly effective HIV-1 vaccine. Characterizing Env-antibody co-evolution in RM that 
develop bNAbs could serve as a roadmap for the development of an effective HIV 
vaccine; studies describing the recapitulation of Env-antibody coevolution in a number of 
RM infected with TF SHIVs that have developed bNAbs are ongoing87. 
 
Goals of this thesis 
Numerous important questions regarding the biology and suitability of SHIVs, 
including TF SHIVs, as an NHP model for HIV-1 infection remain unanswered, including 
those delineated here.  
First, a subset of TF SHIV-infected RM exhibit variable viral persistence. The 
incidence of spontaneous control is dependent on the TF SHIV. For instance, 7 of 30 
non-CD8 depleted SHIV.CH505-infected RM in 3 independent studies controlled viremia 
to around or below 102 c/ml by 12 weeks post-infection88,89,85. The incidence of 
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spontaneous control in SHIV.CH505-infected RM is similar to other SHIVs in use, 
including SHIVs 162P3 and AD871,76. The etiology underlying spontaneous viremic 
control of SHIVs, including TF SHIVs, has never been identified, but could be 
attributable to numerous factors. These factors could include a greater magnitude of 
infection of shorter-lived or aberrant cell subsets, such as Tn76 and/or early development 
of effective host innate and adaptive immune responses that result in differences in the 
clearance and maintenance of reservoir cells in SHIV versus HIV-1 infection. 
Second, there is a dearth of literature that addresses the suitability of SHIVS, 
including TF SHIVs, for latency and cure research. Although multiple groups have and 
continue to use SHIVs AD8 and 162P3 as reagents for preclinical studies of potential 
HIV-1 cure strategies, including latency reversal agents (LRAs)56 and broadly 
neutralizing antibodies57, no study has extensively characterized the reservoir biology 
and pathogenesis of CCR5-tropic SHIVs before, during, and after cART administration in 
the absence of an intervention. Studying SHIVs off and on cART in the absence of an 
intervention would be beneficial for the design of more effective preclinical HIV-1 studies. 
Third, the mechanisms underlying discordant results between preclinical and clinical 
vaccine and other studies have been incompletely elucidated except in the case of SHIV 
89.6. These results could be related to the unusual Env sequence and conformation 
found in both SHIVs 162P3 and AD8 in comparison to TF Envs, the formation of a 
potentially smaller reservoir in SHIV-infected RM versus PLWH due to the reasons 
hypothesized earlier, or the significant genetic distance (up to 70%) between the full-
length chimeric SHIV genome and primary/TF HIV-1 isolates, among others. 
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The goal of this dissertation is to evaluate 2 hypotheses broadly related to these 
questions: 1) that the viral kinetics and reservoir biology of RM infected with TF SHIVs 
both on and off cART recapitulate HIV-1 infection and 2) that serial SHIV passage in 
tandem with mechanistic in vitro studies can be harnessed to engineer a SHIV.CH505 
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A robust simian-human immunodeficiency virus (SHIV)-macaque model of 
latency is critical to investigate eradicative and suppressive strategies that target HIV-1 
Env.  We previously reported a novel strategy for constructing SHIVs that bear primary 
or transmitted/founder (TF) Envs with modifications at Env residue 375 that enables 
efficient replication in Indian rhesus macaques (RM). Such TF SHIVs, however, have not 
been examined for their suitability for HIV-1 latency and cure research. Here, we 
evaluated two promising TF SHIVs, SHIV.D.191859 and SHIV.C.CH848, which encode 
TF subtype D and C HIV-1 Envs, respectively, for their viral kinetics and persistence 
during suppressive combination antiretroviral therapy (cART) and treatment interruption 
in RM using single genome sequencing (SGS) as well as plasma vRNA and cell-
associated DNA and RNA quantification.  
These results suggest that the viral kinetics of these SHIVs in RMs during acute, 
early and chronic infection, and upon cART initiation, maintenance and discontinuation, 
mirror HIV-1 infection. TF SHIVs CH848 and 191859 demonstrate consistent early peak 
and setpoint viremia, rapid declines in viremia to undetectable plasma titers following 
cART initiation, infection of long-lived cellular subsets and establishment of viral latency, 
and viral rebound with return to pretreatment setpoint viremia following treatment 
interruption. The viral dynamics and reservoir biology of SHIV.D.191859, and to a lesser 
extent SHIV.C.CH848, during chronic infection, cART administration, and upon 
treatment interruption suggest that these TF SHIVs are promising reagents for a SHIV 




SHIVs have been successfully used for over two decades to study virus-host 
interactions, transmission, and pathogenesis in rhesus macaques. The majority of Env 
trimers of most previously studied SHIVs, however, do not recapitulate key properties of 
TF or primary HIV-1 isolates, such as CCR5 tropism, tier 2 neutralization resistance, and 
native trimer conformation. Here, we test two recently generated TF SHIVs, 
SHIV.191859 and SHIV.C.CH848, which were designed to address these issues as 
components of a nonhuman primate model of HIV-1 latency. We conclude that the TF 
SHIV-macaque model reflects several hallmarks of HIV and SIV infection and latency. 
Results suggest that this model has broad applications for evaluating eradicative and 
suppressive strategies against the HIV reservoir, including Env-specific interventions, 











Chimeric simian-human immunodeficiency viruses (SHIVs), which encode an 
HIV-1 envelope glycoprotein (Env) within the background of a macaque-adapted simian 
immunodeficiency virus (SIVmac) backbone, have wide-ranging applications for 
evaluating HIV pathogenesis, vaccine and cure strategies67.  SHIVs have been 
successfully used for over two decades to study virus-host interactions, transmission, 
and pathogenesis in non-human primates such as rhesus macaques(RM)67,71,76.  SHIVs 
have particular importance as reagents in studies testing strategies that engage Env, 
such as broadly neutralizing antibodies (bNAbs) and antibody-based vaccines, and in 
dissecting the immunology behind antibody elicitation55–57,79. 
Previous iterations of SHIVs, however, have several limitations.  Many SHIVs do 
not accurately recapitulate key properties of transmitted/founder (TF) or primary HIV-1 
isolates from early infection, such as CCR5 tropism15,32,67,81, infection and depletion of 
relevant long-lived T cell subsets77,78, and induction of consistent autologous tier 2 
antibody responses76,77,24,82. Further, most SHIVs do not fully reflect the original 
conformation and neutralization sensitivity of native HIV-1 Env as a result of adaptations 
acquired through extensive in vitro and in vivo passage required to enable efficient 
infection of RM cells67,71,76.  A small number of SHIVs encoding primary Envs have been 
shown to fortuitously replicate in RM without adaptation; none of these SHIVs, however, 
have been characterized for persistence before, during and after antiretroviral therapy83. 
Recently, we reported the development of a novel strategy to generate designer 
SHIVs encoding native TF or primary Envs with Tier 2 neutralization sensitivity, referred 
to here as “TF SHIVs”84. In this method, a single amino acid substitution at Env position 
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375 mediates increased affinity of HIV-1 Env for rhesus CD4, enabling efficient in vitro 
replication in rhesus cells and in vivo infection of RMs while preserving the antigenic 
properties of the parental Env.  TF SHIVs consistently confer productive infection 
through multiple inoculation routes, high peak viremia, and desirable early viral kinetics.  
Importantly, TF SHIVs are CCR5-tropic and have been shown to reproducibly induce 
autologous antibody responses in infected RM, thereby recapitulating key qualities of 
primary and TF HIV-1 isolates84,87.  Prior to this year, TF SHIVs had not yet been 
evaluated for their suitability for studies of HIV cure and latency.   
Here, we evaluate two genetically and antigenically diverse TF SHIVs, 
SHIV.D.191859 and SHIV.C.CH848, which encode TF subtype D and C HIV-1 Envs, 
respectively, for their viral kinetics and persistence during suppressive combination 
antiretroviral therapy (cART) and treatment interruption in RM.  Our results indicate that 
the kinetics of SHIV.D.191859 and SHIV.C.CH848 infection and replication in RMs 
during acute, early and chronic infection and upon cART initiation and discontinuation 
mirror HIV-1 infection. The findings presented thus provide an experimental framework 
with which to design future preclinical studies of HIV-1 latency, cure and 
immunopathogenesis.  
 
Materials and Methods 
Nonhuman Primates 
Indian-origin RMs were maintained at Tulane National Primate Research Center 
(TNPRC) according to the standards of the Association for Assessment and 
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Accreditation of Laboratory Animal Care. All experiments were approved by the Tulane 
Animal Care and Use Committee.  All animals were tested and found to be negative for 
described SIV controller alleles Mamu-A*01, B*08, and B*17, except for RM DE33, 
which was A*01 positive.  Whole blood from animals was processed using centrifugation 
as described84. PBMCs were isolated using Ficoll-Paque (GE Healthcare) gradient 
centrifugation. Plasma was clarified by centrifugation for 15 min at 3000 rpm, frozen, 
thawed, and then subject to viral RNA extraction as described below.  SHIV VL levels in 
plasma were determined by the Pathogen Detection and Quantification Core at the 
TNPRC using quantitative real-time reverse-transcription PCR of SIV RNA as previously 
described90; the assay limit of quantification (LOQ) was 83 c/ml.  
 
Construction and Viral Stock Characterization of SHIV.D.191859 and 
SHIV.C.CH848 
SHIV.D.191859 and SHIV.C.CH848 constructs were generated and viral stocks 
were made as described84. Briefly, for the 293T-derived SHIV.C.CH848 stock, 6 ug of 
plasmid DNA and 18 ul of FuGENE 6 (Promega) transfection reagent were added to a 
pre-seeded Petri dish containing 3.6X106 293T cells in 10 mL of complete media (DMEM 
with Glutamax (Gibco) supplemented with 10% FBS (Hyclone) and 100 U/ml 
penicillin/streptomycin (Gibco)). After 48 hours, the supernatant was transferred to a 15 
mL conical and spun at 3000 rpm for 15 minutes. The clarified viral supernatant was 
aliquoted and frozen at -80C. The rhesus CD4-derived SHIV.D.191859 stock was 
generated as described in 84 
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The virion content of viral stocks was quantified in triplicate using the p27Ag 96-
well ELISA kit from ZeptoMetrix; the manufacturer’s instructions were followed without 
deviation. The infectivity of viral stocks was determined via titration on TZM-bl cells in 
quadruplicate.  Briefly, TZM-bl cells were obtained from the NIH AIDS Reagent Program. 
10,000 cells/well were seeded in a 96-well tissue culture plate in 100 ul/well complete 
media (DMEM with Glutamax (Gibco) supplemented with 10% FBS (Hyclone) and 100 
U/ml penicillin/streptomycin (Gibco)). The following day, virus stocks were serially diluted 
5-fold in complete media supplemented with 40 ug/ml of DEAE-Dextran (Thermofisher) 
in titer tubes, with an initial virus stock dilution of 1:5. Virus stock dilutions were 
transferred in quadruplicate to TZM-bl cells. After 48 hours, cells were stained with beta-
galactosidase and infectious titer was calculated as described in 91.  
Virion content for the rhesus PBMC-derived SHIV.D.191859. and 293T-derived 
SHIV.C.CH848 stocks were 211 and 2342 ng p27Ag/ml, respectively. The 
SHIV.D.191859 and SHIV.C.CH848 infectivity-to-particle ratios as determined on TZM-bl 
cells were 1.510-2 and 5.510-4 IU/particle, respectively, which is similar to other TF 
SHIV stocks84. 
 
SHIV.D.191859 and SHIV.C.CH848 Inoculation 
Six RM were intravaginally challenged with one mL of undiluted 
SHIV.D.191859.dCT containing 3.19107 infectious units (IU) as determined on TZM-bl 
cells.  Two RM (FE43 and EJ94) became productively infected following the first 
challenge. 4 RM that remained uninfected were intravaginally challenged with one mL of 
26 
 
stock dilutions of 1:10 at week 12, 1:4 at week 16, and 1:2 at week 23.  After four 
challenges, two RM (FR55 and GA67) remained uninfected; these RM were 
intravenously inoculated with 1.00106 IU of SHIV.D.191859 at week 48, which resulted 
in productive infection of both animals.  In a separate study, four RM were intravenously 
challenged with one mL of undiluted SHIV.C.CH848.dCT stock containing 1.29107 
infectious units (IU) as determined on TZM-bl cells; all RM became productively infected. 
 
Viral Sequencing 
Single-genome gp160 env sequences were generated as described84.  Briefly, 
20,000 viral RNA copies were extracted from plasma by means of the Qiagen BioRobot 
EZ1 Workstation with the EZ1 Virus Mini Kit v2.0 (Qiagen).  Eluted vRNA was 
subsequently used as a template for cDNA synthesis and reverse-transcribed using the 
reverse primer SHIV.Env.R1 (5′- TACCCCTACCAAGTCATCA-3′) and SuperScript III 
reverse transcriptase (Invitrogen Life Technologies). cDNA was serially diluted in a 96-
well plate (Applied Biosystems) to identify the dilution at which less than 30% of wells 
contained PCR amplicons of the correct size.  The SHIV gp160 env genome was 
amplified via nested PCR with primers as follows: first round forward primer 
SHIV.Env.F1 (5′- CGAATGGCTAAACAGAACA-3′), second round forward primer 
SHIV.Env.F2 (CTACCAAGGGAGCTGATTTTC), first round reverse primer SHIV.Env.R1 
(5′- TACCCCTACCAAGTCATCA-3′), and second round reverse primer SHIV.Env.R2 5’-
TATTTTGTTTTCTGTATGCT-3’). PCR conditions were used as follows for the first 
round of nested PCR: 94°C, 2 min; 37x [94°C, 20 sec; 55°C, 30 sec; 68°C, 3 min 30 
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sec]; 68°C, 10 min. For the second round of nested PCR, the PCR conditions were as 
follows: 94°C, 2 min; 42x [94°C, 20 sec; 54°C, 30 sec; 68°C, 3 min 30 sec]; 68°C, 10 
min. Amplicons were sequenced via the MiSeq platform (Illumina). Raw reads were 
aligned to the SHIV.D.191859 or SHIV.C.CH848 TF reference using Geneious R9. 
Sequences that contained mixed bases at a frequency of greater than 25% per 
nucleotide position were excluded from further analyses.   
 
TF Estimation 
To approximate the minimum number of virus-infected cells that contributed to 
recrudescent viremia, we generated a conservative estimate of the amount of genetic 
diversity that could accrue in the time elapsed post-ATI.  We used the median error rate 
for HIV-2 reverse-transcriptase (RT) reported by Rawson et al.92 (3.110-4 
mutations/nucleotide base), as SIVmac is more closely related to HIV-2 than HIV-17; of 
note, error rates for both HIV-1 and HIV-2 RT are reported to be very similar93.  We 
assumed a virus-infected cell generation time of 1.5 days based on previous 
studies21,22,94. We multiplied HIV-2 RT error rate (3.110-4 mutations/nucleotide base) by 
average TF SHIV gp160 env amplicon length (3693 bp) and divided this number by the 
virus-infected cell generation time (1.5 days) to estimate the amount of genetic diversity 
that could accrue in a day. We then multiplied the resulting number by the number of 
days elapsed post-ATI to estimate the maximum amount of genetic diversity that could 
accrue in each virus population during this period, subtracting four days from the number 
of days elapsed post-ATI to account for a conservative terminal drug washout period 
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based on previous pharmacokinetic elimination studies in HIV-1-infected humans95. The 
equation used for estimating the maximum accrued diversity post-ATI for each RM is 
thus summarized as: (3.110-43,693(days elapsed post-ATI-4))/1.5.  Data regarding 
the complete pharmacokinetic elimination and drug metabolism of tenofovir, 
emtricitabine, and dolutegravir in HIV-1 infected humans and SIV and SHIV-infected 
rhesus macaques are limited, to date96–98. This estimate was used to determine the 
maximum divergence one reactivating lineage unaffected by recombination could accrue 
during ATI, which allowed us to enumerate the minimum number of independent 
reactivation events during systemic viral rebound at the time of sampling based on 
divergence from neighboring lineages.  
 
Phylogenetic Analyses 
Maximum-likelihood phylogenetic trees were generated using the HKY85 
substitution model and a transition/transversion ratio of four in PhyML Version 3.0 and 
visualized in FigTree99.  Maximum pairwise diversity measurements of pre and post-
cART virus populations were calculated using DIVEIN100. 
 
Flow Cytometric Sorting of PBMC and LNMC 
Antibodies used for CD4 T cell subset sorting. The following antibodies were 
obtained from Biolegend: CD8 AF647 (clone RPA-T8), CD14 BV650 (clone M5E2), 
CD16 BV650 (clone 3G8) and CD20 BV650 (clone 2H7). The following antibodies were 
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obtained from BD Biosciences: CD3 APC-Cy7 (clone SP34-2), CD95 PE-Cy5 (clone 
DX2), HLA-DR BV421 (clone G46-6). CD28 ECD (clone CD28.2) was obtained from 
Beckman Coulter. CD4 PE-Cy5.5 (clone S3.5) was obtained from Life Technologies. 
The Live/Dead Fixable Aqua Dead Cell Stain Kit (Invitrogen) was used for viability 
exclusion.  
Sorting for CD4+ T cell subsets. Cryopreserved PBMC or LNMC were thawed, 
counted, examined for viability and rested for two hours at 37°C and 5% CO2 in 
complete medium (RPMI supplemented with 10% FBS, 2 mM L-glutamine, 100 U/ml 
penicillin, and 100 mg/ml streptomycin). All incubation ns were performed in the dark at 
room temperature. Cells were stained for viability exclusion for 10 minutes. Undiluted 
antibody cocktail mix was added and incubated for 20 minutes. Following surface 
staining, cells were washed and resuspended in phenol-free RPMI, and kept in the dark 
at 4°C. Cells were sorted on a FACSAria II (BD Biosciences). Sorted cells were washed 
with PBS and pelleted at -80°C until processing. Tn were identified as CD28+ CD95- 
CD4 T cells. Tcm were identified as CD28+ CD95+ CD4 T cells. Resting memory CD4 T 
cells were identified as CD95+ HLA-DR- CD4 T cells. 
 
Quantification of Cell-Associated SHIV DNA and RNA in PBMC and Tissues 
     Cellular DNA was purified using the AllPrep DNA/RNA kit (Qiagen) as specified by 
the manufacturer and normalized to cell equivalents by qPCR using a non-human 
primate-specific TaqMan hRNase P primer-probe assay (Life Technologies). Total 
cellular SHIV DNA was quantified in a qPCR reaction using primers and probe specific 
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to the SIVmac239 LTR region (Forward Primer: 5’-
TACCCAGAAGAGTTTGGAAGCAAGTCA-3’, Reverse Primer: 5’-
TTGTCAGCCATGTTAAGAAGGCCTCTTG-3’ and Probe A: 5’-(FAM) 
CTGTCAGAGGAAGAGGTTAGAAGAAGGCTAAC (BHQ1)-3’ (Integrated DNA 
Technologies). PCR reaction mixtures each contained 10 µl of 2X Taqman Universal 
Master Mix II (Life Technologies), 6 pmol of each primer, 6 pmol of probe, and 5μl of 
DNA (total volume of PCR reaction = 20 ul). PCR cycle conditions were as follows: 
50°C, 2 min; 95°C, 10 min; 50x [95°C, 15s; 60°C,1 min); PCR was performed on an ABI 
7500 FAST machine (Life Technologies).  External quantitation standards were prepared 
using DNA isolated from the SIV1C cell line, which has a single copy of SIV DNA per 
cell; this was followed by copy number determination using RainDance Digital Droplet 
PCR (RainDrop). Specimens were assayed in replicate reaction wells.  Copy number 
was determined by extrapolation against an 8-point standard curve (1–100,000 copies), 
which was performed in triplicate. Due to low viable PBMC and LNMC recovery for some 
SHIV.C subset samples, the ca-DNA LOQ varied, and ranged between 20 to 1500 
copies per sample (Figure 2.6D-F). Similarly, ca-RNA measurements for two SHIV.D-
infected RM (RM FE43 and GA67) were not detectable at month six due to low cell 
yields and therefore were excluded from Figure 2.2B. 
 
qPCR quantification of cellular SIV RNA. Cellular RNA was purified using the 
AllPrep DNA/RNA kit (Qiagen) as specified by the manufacturer and was normalized to 
cell equivalents by qPCR using the non-human primate-specific TaqMan RPLPO primer-
probe assay (Life Technologies). Total cellular SHIV RNA was quantified using a two-
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step RT-PCR assay. First, 250 ng of RNA were reverse transcribed to produce cDNA 
using the VILO IV reverse transcriptase enzyme and random hexamer primers 
(Invitrogen) according the manufacturer’s instructions.  cDNA was quantified in a qPCR 
reaction using primers and a probe specific to the SIVmac239 LTR region (Forward 
Primer: 5’-TACCCAGAAGAGTTTGGAAGCAAGTCA-3’, Reverse Primer: 5’-
TTGTCAGCCATGTTAAGAAGGCCTCTTG-3’ and Probe A: 5’-(FAM) 
CTGTCAGAGGAAGAGGTTAGAAGAAGGCTAAC (BHQ1)-3’ (Integrated DNA 
Technologies)). Each reaction contained 10 µl of 2X Taqman Universal Master Mix II 
(Life Technologies), 6 pmol of each primer, 6 pmol of probe, and 5μl of cDNA, with a 
total reaction volume of 20 ul.  PCR cycle conditions were as follows: 50°C, 2 min; 95°C, 
10 min; 50x [95°C, 15s; 60°C,1 min); PCR was performed on an ABI 7500 FAST 
machine (Life Technologies).  qPCR runs were carried out using an ABI 7500 FAST 
Machine (Life Technologies).  External quantitation standards were prepared using 
SIVmac239 RNA followed by copy number determination using the RainDance Digital 
Droplet PCR (RainDrop, MA). Specimens were assayed in replicate reaction wells.  
Copy number was determined by extrapolation against a 6-point standard curve (3–
300,000 copies), which was performed in triplicate.  
 
Logo plot generation. 
For each RM, sequence alignments from pre-cART and first detectable rebound 
were compared. Any amino acid position with greater than 20% change in identity 







Statistical analyses were performed using Prism 7.0 software (Graphpad). Given 
small sample sizes (n=4 to 6), nonparametric tests were used for all statistical 
comparisons. The Wilcoxon signed-rank test was used to test for changes in within-
animal measures of viral diversity and latency pre- and post-cART administration. 
Spearman’s rank-order correlation test was used to assess the association between 
measures of latency. The Mann-Whitney test was used to assess the relationship of ca-
DNA and ca-RNA levels in PBMC in RM infected with SHIV.D versus SHIV.C. 
 
Results 
SHIV.D.191859 and SHIV.C.CH848 early viral kinetics.  
Two TF SHIVs with desirable viral kinetics, SHIV.D.191859 and SHIV.C.CH848, 
hereafter referred to as SHIV.D and SHIV.C, were evaluated for their suitability for 
latency and cure studies.  SHIV.D encodes a subtype D TF Env identified from an 
acutely infected Ugandan woman in 200832.  The HIV-1 TF virus was shown to be 
CCR5-tropic, with a tier 2 neutralization profile and the capacity to replicate in both CD4 
T cells and macrophages32.  SHIV.C encodes a clade C Env identified in an acutely-
infected Malawian man in 2008101. Subsequently, infection with this virus was shown to 
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elicit N332-dependent V3-targeting bNabs after 3.5 years of infection.  A strategy for 
eliciting CH848-like bNabs in humans via vaccination has been described101; further, 
similar bNabs have been elicited in SHIV.C.CH848-infected RM87. Prior to the current 
study, SHIV.D and SHIV.C had each been used to infect 6 non-CD8 depleted RM, with 
mean peak VLs of 106-7 c/ml for both SHIVs; 10 of 12 SHIV.C and SHIV.D-infected RM 
maintained viremia above 103 c/ml through 24 weeks post-infection (WPI)84  
 
 SHIV.D.191859 persists on suppressive cART. 
To evaluate SHIV.D infection after early time points and its response to cART, 6 
RM were intravaginally challenged with increasing doses of SHIV.D until infection was 
confirmed by repeated positive plasma VL (VL) measurements.  2 RM demonstrated 
infection after the first challenge and 2 additional RM became productively infected after 
the third challenge (Figure 2.1). 2 RM remained uninfected after 4 intravaginal 
challenges and were subsequently inoculated intravenously, demonstrating productive 
infection at day 7. Peak viremia ranged from 9.7105 to 4.2107 c/ml and levels did not 
appear substantially different between animals infected by mucosal versus intravenous 
routes (mean peak VL = 1.4107 c/ml versus 2.1106 c/ml, respectively).  
RM were followed longitudinally through early infection and establishment of a 
relatively stable viral set point (Figure 2.1). In all 6 RM, viremia above 103 c/ml was 
maintained for at least 24 weeks, with set point VLs ranging from 103 to 106 c/ml. After 
42 WPI, RM FT42 spontaneously controlled plasma viremia to below the assay LOQ (83 
c/ml) and was excluded from further analysis.  RM DE33 was euthanized at 66 WPI after 
34 
 
viremia rose to greater than 106 c/ml coincident with signs and symptoms of severe 
illness; this RM was positive for the Mamu A*01 allele, which is significantly associated 
with frequency of spontaneous viremic control of SIV infection102. In this small cohort, the 
mean set point VL did not appear to be substantially different between animals that were 
productively infected via mucosal or intravenous inoculation (mean set point VL = 
3.0105 versus 1.6105 c/ml, respectively). 
 We evaluated persistence of SHIV.D on suppressive cART in the 4 remaining 
viremic RM using daily injectable combination antiretroviral therapy (cART) consisting of 
dolutegravir, emtricitabine, and tenofovir. Viral suppression below 83 c/ml was achieved 
between 7 to 21 days of cART initiation and durably maintained in all RM.  One 
incidence of detectable viremia to 804 c/ml occurred in EJ94 16 weeks post-cART 
initiation. cART was discontinued after 24 weeks.  Rebound plasma viremia was 
detected between 7 and 19 days post-treatment interruption (Figure 2.1). Plasma virus 
rebounded to at or near the pre-cART set point VL in all RM (103 to 107 c/ml by four 
weeks post-rebound).  
We next quantified the levels of cell-associated viral DNA (ca-DNA) and RNA 
(ca-RNA) in PBMCs sampled during chronic infection in SHIV.D-infected RM prior to 
cART initiation (Figure 2.2).  The mean ca-DNA measurement in PBMC was 9.9102 
copies/106 cells and remained detectable after four months of cART suppression in all 
four RM, with a mean 1.9-fold decrease.  The mean ca-RNA level was 5.4103 
copies/106 cells and similarly decreased 2.0-fold, on average, after four months of cART.  




SHIV.D.191859 diversity pre- and post-cART  
We next characterized the diversity of SHIV populations by longitudinal single 
genome sequencing (SGS) of gp160 env sequences; 284 total sequences (median 31 
per animal timepoint) were generated. To characterize peri-maximal SHIV diversity, 
plasma virus was sequenced immediately prior to cART-initiation, when the four RM had 
been productively infected for between 33 to 81 weeks (Figure 2.3), revealing a 
maximum within-animal env pairwise diversity between 1.0-2.5%. 
 To characterize the rebound virus populations reactivating from latency upon 
treatment interruption, sequences were generated from the first time point where plasma 
VL was greater than 500 c/ml. Maximum likelihood phylogenetic trees comparing the TF 
SHIV.D env sequence and pre-cART and rebound plasma virus populations are shown 
in Figure 2.3. Maximum within-animal pairwise diversity values at the time of first 
detectable rebound were not significantly different from pre-cART values, ranging from 
0.3-1.9% (p=0.25, n=4, Wilcoxon signed-rank test).  
To enumerate the minimum number of virus-infected cells that contributed to 
recrudescent viremia, we used a conservative estimate of the amount of genetic 
diversity that could accrue in the elapsed time post-treatment interruption.  For these 4 
RMs, the maximum diversity estimate discriminating between variants ranged between 
three and 19 nts per env sequence, based on differences in time to rebound (see 
methods). For example, RM EJ94 had the fastest time to rebound of the four RM (seven 
days). Given an estimated mutation rate of 0.76 nt per amplified viral genome per day, 
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time to rebound, and an approximate terminal drug washout period of four days, we infer 
that the maximum divergence one reactivating lineage could accrue within env between 
reactivation and our sampling is two nucleotide substitutions.  Thus, virus lineages that 
differ in env by more than two nucleotides are likely representative of distinct reactivating 
cells. FE43, in contrast, had the slowest time to rebound (19 days). For this RM, our 
model likely overestimates the maximum divergence one reactivating lineage could 
accrue, as virus is unlikely to be consistently replicating for 15 days prior to systemic 
detection. Using this diversity cut-off, rebound virus populations in the four RM grouped 
into between seven (FE43), ten (FR55), and 13 (EJ94) low-diversity lineages at first 
detectable viral rebound in three of four RM. In GA67, sequences fell into either one or 
two closely related lineages at day 12 post-ATI. One week later, at day 19 post-ATI, six 
genetically distinct low-diversity lineages were sampled in RM GA67. Thus, in all four 
RM, rebound viremia was founded by multiple virus-infected cell reactivations.  
 
SHIV.D.191859 and CD4 T cell quantification in tissues 
To assess the extent of systemic virus dissemination and CD4 T cell depletion in 
SHIV.D-infected RM, we quantified CD4 T cell percentage, total SHIV DNA, and total 
SHIV RNA in lymphoid and other tissues following euthanasia due to either clinical 
indication or study end point. RM DE33 and EJ94 were euthanized due to clinical 
disease progression at 18 and 39 months post-infection MPI), respectively. RM FR55 
and GA67 were re-suppressed on cART at 39 and 34 MPI, respectively. RM FR55 was 
electively euthanized 6 months later at 45 MPI, while RM GA67 was euthanized due to 
37 
 
clinical indication at 35 MPI after one month of cART re-suppression. RMs FE43 and 
FT42 were euthanized per study protocol; FE43 while viremic at 40 MPI and RM FT42 
while virally suppressed off cART at 36 MPI, after 25 months of spontaneous virus 
control. In the two RM with clinical progression coincident with high viremia, CD4 T cells 
were depleted and levels of HIV DNA and RNA high throughout the body. In RM EJ94, 
analysis of PBMC and all lymphoid tissues, including gut-associated lymphoid tissues 
(GALT), spleen, and lymph nodes, revealed severe CD4 T cell depletion at necropsy 
(0.9-2.5% of total T cells, Figure 2.4A). In RM DE33, a similarly severe degree of CD4 T 
cell depletion was observed in GALT, including the colon and ileum (4.7 and 6.0% of 
total T cells, respectively) as well as in bone marrow (7.0%, Figure 2.4A). In RM with 
less SHIV-associated disease progression, CD4 T cell depletion was more moderate 
and levels of SHIV DNA and RNA lower throughout.   Despite spontaneously 
suppressing plasma viremia, RM FT42 had detectable ca-DNA and RNA in multiple 
tissues at necropsy.  Across the six RM, SHIV DNA and RNA quantification showed 
systemic virus dissemination in every tissue sampled from all SHIV.D-infected RM, 
which included GALT, lymph nodes, tonsil, and spleen (Figure 2.4B-C). The mean total 
SHIV DNA and RNA measurements across all sampled tissues in all RM were 3.4104 
and 2.9107 copies/106 cells, respectively (Figure 2.4B-C). 
 
SHIV.C.CH848 infection pre- and post-cART. 
We next examined SHIV.C infection for persistence on cART.  Four RM were 
intravenously challenged with a high-dose SHIV.C inoculum. All animals became 
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productively infected with peak VL ranging from 105 to 107 c/ml (Figure 2.5).  In all four 
RM, viremia was maintained through 16 WPI, with set point VLs ranging from 103 to 105 
c/ml.  After 16 weeks of infection, cART was initiated. Viral suppression below 83 c/ml 
was achieved in all RM within seven days post-cART initiation and was durably 
maintained for 24 weeks.  cART was discontinued at 24 weeks post-infection, with 
recrudescent plasma viremia detected within five to 22 days of treatment interruption. As 
with SHIV.D-infected animals, RM with higher pre-cART viremia rebounded earlier 
(Figure 2.5).  Post-rebound, the four RM re-established a quasi-set point VL at ~1-1.5 
log10 c/ml below pre-cART levels. For KK54, this led to consistent viremia (~104 c/ml). 
For the remaining three RM, lower levels of systemic virus replication were detected 
post-ATI, with intermittent declines of viremia below 83 c/ml.  In KH83, the animal with 
the lowest viremia pre-cART, virus initially rebounded shortly post-ATI, but then fell to 
below the limit of assay detection one week later and remained undetectable for 21 
weeks until rising to 103 c/ml through 24 weeks post-rebound.  The two RM with 
intermediate VLs pre-cART had post-rebound viremia that ranged from less than 102 to 
greater than 103 c/ml through 24 weeks.  
We then quantified the levels of ca-DNA and ca-RNA in SHIV.C-infected PBMC 
at peak infection (3 WPI), at chronic infection (12 WPI), and after 12 weeks of cART to 
characterize the dynamics of PBMC infection throughout the course of the study (Figure 
2.6). At peak infection, the mean ca-DNA and ca-RNA measurements were 6.0103 and 
6.9105 copies/106 cells, respectively (Figure 2.6A-B). During chronic infection, ca-DNA 
and ca-RNA levels decreased to 7.8102 and 3.9103 copies/106 cells, respectively 
(Figure 2.6A-B). The levels of ca-DNA and ca-RNA in chronic SHIV.C infection were 
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similar to chronic SHIV.D infection (p=1 and 0.89, respectively, n=4, Mann-Whitney test). 
Notably, after 3 months of cART administration, ca-DNA and ca-RNA decreased less 
than 1 log10 to 3.5102 and 7.3102 copies/106 cells, respectively (Figure 2.6A-B). 
To provide greater understanding of latency measures in long-lived cell 
populations, we sampled PBMC and lymph node mononuclear cells (LMNC) and 
quantified ca-DNA in several T cell subsets over time: central memory CD4 T cells (Tcm), 
naïve CD4 T cells (Tn), and total resting memory CD4 T cells (Figure 2.6D-F). In all 
assayed subsets, the magnitude of infection was highest at peak infection (3 WPI), 
decreased by 4.6-fold across all subsets during chronic infection (15 WPI), and further 
decreased by 3.2-fold after 22 weeks of cART (Figure 2.6D-F). Tcm ca-DNA was highest 
in both PBMC and LNMC at peak infection (mean = 4.7104 copies/106 cells), decreased 
by 6.1-fold after 15 WPI (mean = 7.7103 copies/106 cells) and further decreased by 3.9-
fold after 22 weeks of cART (mean = 2.7103 copies/106 cells, Figure 2.6D).  Notably, 
ca-DNA in this long-lived subset remained detectable in all RM despite more than 20 
weeks of cART suppression.  In Tn and total resting memory CD4 T cells, decay kinetics 
upon cART initiation were comparable to Tcm (Figure 2.6E-F). Total resting memory T 
cells and Tcm were infected at a similar magnitude at peak and chronic time points, while 
Tn were infected at a decreased frequency at peak and chronic infection (mean = 6.8 
and 4.8103 copies/106 cells, respectively, Figure 2.6D-F) 
 
SHIV.C.CH848 diversity before and after suppressive cART.  
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We next characterized the diversity of SHIV populations by SGS of gp160 env 
sequences. A total of 341 sequences (median 27 per animal timepoint) were generated. 
To characterize peri-maximal env diversity, plasma virus was sequenced two weeks 
prior to cART initiation at 14 WPI (Fig 7). SGS sequences revealed a maximum within-
animal pairwise diversity of 0.7-1.2%. Rebound plasma was sampled twice weekly post-
treatment interruption and sequences were generated from the time of first detectable 
rebound. Maximum likelihood phylogenetic trees comparing pre-cART and rebound 
plasma virus env sequences with the TF SHIV.C env sequence are shown in Figure 2.7. 
Maximum within-animal pairwise diversity measurements at the time of first detectable 
rebound were not significantly different from pre-cART values (range = 0.1-0.8%, 
p=0.13, n=4, Wilcoxon signed-rank test). At first detectable rebound, we sampled 
multiple genetically distinct virus populations in three of four RM.  Rebound virus 
sequences clustered into between three and 11 discrete low-diversity lineages. The 
exception, RM KH83, exhibited a monoclonal virus population at rebound and had 
correspondingly low diversity measures (0.1%). While the rebounding virus population 
was polyclonal in three of four RM, fewer rebound lineages were identified in SHIV.C 
versus SHIV.D-infected RM. 
To determine whether virus populations persisted through periods of control or 
were cleared and replaced with novel viruses, plasma virus was sequenced 
longitudinally (Figure 2.7).  In both KM65 and KM11, we found that the lineages present 
at first detectable rebound persisted over time despite intermittent periods of 
undetectable (<83 c/ml) viremia.  In KM65, for example, at first detectable rebound (15 
days post-ATI), three distinct low-diversity lineages were present.  Sequences from 19 
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days post-ATI were identical or closely related (one to three nt different) to those at 15 
days post-ATI, with two additional low-diversity lineages sampled.  Sequences from day 
56 post-ATI, which followed a short period of spontaneous control, formed 1 distinct low-
diversity lineage that was closely related (one to eight nt different) to lineages sampled 
at 15 and 19 days post-ATI. Similar results were identified in RM KM11 at days 42 and 
49 post-ATI following a period of viral suppression (Figure 2.7). In RM KK54, which 
maintained viremia above the assay LOQ throughout the post-rebound period, four of 11 
virus lineages sampled at first detectable rebound (12 days post-ATI) persisted at 22 
and 29 days post-ATI.  An additional six and four distinct lineages were sampled at 22 
and 29 days post-ATI, respectively. 
 
Rebound virus population diversity.  
To assess how virus populations changed in response to cART treatment, we 
compared pre-ART and rebound virus sequences.  Shown in Figure 2.8 are LOGO plots 
depicting all amino acid positions with greater than 20% change in identity between pre-
cART and rebound plasma virus populations.  The vast majority of positions, not shown 
in the LOGO plots, were relatively fixed from pre-cART to rebound.  In positions with 
diversity in virus replicating at cART initiation, overall diversity modestly decreased. This 
was most notable in RM with mono- or oligoclonal rebound, e.g., GA67, KH83, and 
KM65.  RM that went on to experience post-rebound control generally had fewer 
rebound variants and thus less virus diversity at rebound.  Beyond lower relative 
diversity, we found no specific sequence signature of post-rebound virus control. In the 
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majority of studied RM that experienced polyclonal rebound, pre-cART virus diversity 
was better retained at rebound, albeit with shifts in relative frequencies at specific 
positions. At rare positions in RM with greater numbers of rebounding viruses, virus 
diversity increased at select positions, as either minor or ancestral variants rebounded to 



































Figure 2.1. SHIV.D.191859 viremia over time.  A. Plasma viremia (c/ml, y axis) is 
depicted longitudinally with week post-infection indicated on the x axis. Mucosal 
inoculation is indicated by a black arrow; intravenous inoculation is indicated by a red 
arrow. Euthanasia is indicated by a black cross. Time of cART administration (24 weeks) 
is shown as a shaded grey box. B. Time to virus suppression after cART initiation and 









































































Figure 2.2. SHIV.D.191859 quantification over time. Cell-associated DNA levels in 
PBMC (A), cell-associated RNA levels in PBMC (B), and matched plasma VL 
measurements (C) are shown for all SHIV-infected RM.  Pre-cART samples were 
obtained during chronic infection (>33 WPI); a second and third set of samples were 
obtained after 16 (month 4) and 23 (month 6) weeks of cART suppression, respectively. 
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Figure 2.3. Phylogenetic trees of longitudinal SHIV.D.191859-infected RM env 
sequences. The TF SHIV.D sequence is shown in pink, pre-cART sequences are 
shown in black, sequences from the first and second weeks of detectable viremia after 
ATI are shown in blue and orange, respectively. Genetic distance is indicated by scale 
bar, indicating 10 nucleotides or ~0.3% difference. Sequences are shown from RM EJ94 
























Figure 2.4. SHIV.D.191859 and CD4 T cell quantification in tissues. CD4 T cell 
percentages (A), total SHIV DNA (B), and total SHIV RNA (C) are shown for tissues from 
all SHIV.D-infected RM at necropsy. Euthanasia was performed at different timepoints, 
for clinical indications or at study completion. RM DE33 and EJ94 were euthanized while 
viremic for clinical indication at 18 and 39 study months, respectively. RM GA67 and 
FR65 were euthanized while on cART; FR55 after 6 months of cART by study protocol 
and GA67 after 1 month of cART due to clinical deterioration.  FE43 was euthanized 
while viremic at study month 40. RM FT42 spontaneously controlled viremia to below the 
assay LOQ and was euthanized with suppressed virus off cART. MLN = mesenteric 
lymph node, ALN = axillary lymph node, BM = bone marrow, PLN = pharyngeal lymph 


























Figure 2.5. SHIV.C.CH848 viremia over time. A. Plasma viremia (c/ml, y axis) is 
depicted longitudinally with week post-infection indicated on the x axis. Intravenous 
inoculation is indicated with a red arrow. Time of cART administration (24 weeks) is 
shown as a grey box. B. Time to virus suppression after cART initiation and time to 
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Figure 2.6. SHIV.C.CH848 quantification over time. A. Cell-associated DNA levels in 
PBMC, cell-associated RNA levels in PBMC, and matched plasma VL measurements 
are shown for all RM.  Cell-associated DNA levels in PBMC (B) and LNMC-derived (C) 
Tcm, Tn, and total resting memory CD4 T cells are shown for all RM. Samples were 
obtained at baseline (2 weeks prior to inoculation), during peak infection (3 WPI), during 
chronic infection (15 WPI), and on cART (38 weeks post-cART). Limit of quantification 

















Figure 2.7. Phylogenetic trees of longitudinal SHIV.C.CH848-infected RM env 
sequences. TF reference sequence is shown in pink, pre-cART sequences are shown 
in black, sequences from the first, second, and third longitudinal rebound time points 
following ATI are shown in blue, orange, and green, respectively. Genetic distance is 
indicated by scale bar, indicating 10 nucleotides, or ~0.3% difference. All RM were 
viremic for 16 weeks prior to cART initiation. A. Rebound sequences from RM KH83 at 
29 days post-ATI.  B. Rebound sequences from RM KM11 at days 19, 42, and 49 post-
ATI. C. Rebound sequences from KM65 at days 15, 19, and 56 post-ATI. D. Rebound 
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Figure 2.8. Rebound virus diversity. Logo plots depicting amino acid positions with 
greater than 20% change in identity between pre-cART and rebound timepoints are 
shown for each RM.   Variable positions from pre-cART and first detectable rebound 
(R1) are shown for each RM. The second timepoint of rebound (R2) is shown for RM 
GA67, in which additional rebound lineages arise a week after the R1 timepoint. The 
third rebound timepoint is shown for KK54, which experienced persistent viremia post-





















NHP models of HIV/AIDS have been fundamental to elucidating key features of 
HIV transmission, pathogenesis, persistence and response to therapy.  As the field 
continues to explore cure strategies, development of an NHP model that mirrors key 
features of HIV persistence is essential. A model with viruses encoding primary HIV-1 
Envs facilitates more direct testing of HIV-1 Env-targeting strategies and is a priority.  
Here, we tested the capacity of two TF SHIVs to demonstrate key features of HIV-1 
replication and persistence on cART. We found that both SHIV.C and SHIV.D 
reproduced important characteristics of HIV-1 infection.   
For an ideal virus in the NHP model system, recapitulation of key components of 
each stage of infection is important, with acute HIV infection being paramount as the 
host-pathogen balance may be established at the earliest stages of infection.  In acute 
HIV infection, peak VLs can reach greater than 106 – 107 c/ml with systemic virus 
dissemination103,104. Following the exhaustion of target cells and the onset of adaptive 
immune responses, a mean set point VL of between 103 – 105 c/ml is established, albeit 
with substantial variation by individual103,104. Both SHIV.C and SHIV.D-infected RM 
demonstrated the consistent timing and magnitude of early virus replication previously 
seen with TF and other SHIVs, with peak viremia of between 105 – 108 c/ml within 7-14 
days post inoculation67,71,76,84. Both SHIVs studied here established setpoint VLs of 
between 103 – 106 c/ml through either 24 weeks post-infection or until initiation of cART 




After early viral kinetics, a high priority for viruses used in cure studies is their 
response to cART, in terms of the time to suppression after cART initiation, persistence 
on longer-term cART, and viral rebound after cART interruption.  Upon cART initiation, 
all TF SHIV-infected NHP rapidly achieved virus suppression below assay limit of 
detection, with the majority achieving undetectable levels within two weeks.  This 
timeframe is slightly more rapid than in HIV-1 infection, where cART containing an 
integrase strand transfer inhibitor leads to viremia of less than 200 c/ml within one to two 
months of cART initiation in most individuals34.   
All 8 TF SHIV-infected RM maintained virus suppression with 24 weeks of cART, 
with a single RM demonstrating a transient period of breakthrough viremia.  Upon cART 
interruption, the time to virus rebound was akin to that of chronic cART-initiating PLWH 
in treatment interruption trials. All TF SHIV-infected RM rebounded between 5 and 22 
days (mean = 12 days), which aligns well with the 85% of ATI trial participants who 
rebound within four to 47 days (mean = 11 days)38,39.  We note the modest variability in 
the reactivation rate of these animals, which is similar to the heterogeneity in time to 
rebound in HIV positive individuals undergoing ATI.  In sum, the viral kinetics of TF SHIV 
infection before, during, and after cART provide a reasonable approximation of HIV-1 
infection, with similar average set point VL and recapitulation of some of the variability 
seen in PLWH. 
The kinetics of TF SHIV infection prior to, during, and after cART differ from 
SIVmac239 infection, which is one of the most frequently used NHP model systems.  
SIVmac239 is a highly virulent clonal strain, which leads to a consistent and pathogenic 
disease course in RM.  By inducing a rapid progressor phenotype65 characterized by 
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accelerated disease progression, elevated inflammatory markers, and impaired immune 
responses, SIVmac239 infection of RM can be harnessed for more efficient and 
economical experiments with fewer animals and shorter duration to clinical endpoints. 
Compared to TF SHIVs and the majority of people living with HIV, SIVmac239 infection 
leads to higher peak (mean = 107-8 c/ml65,105 and set point (mean = 106 c/ml102) viremia in 
comparison to both TF SHIV and HIV-1 infection.  Further, SIVmac239 infection typically 
requires more than four months of cART administration to achieve virus suppression, 
which may impose financial and temporal constraints for latency and cure 
experiments60,64.   
The mechanisms underlying differences in TF SHIV and SIVmac239 viral kinetics 
both off and on cART are likely primarily due to the enhanced virulence of SIVmac239.  
Other related factors, including increased set point viremia, immune dysregulation, 
microbial translocation, chronic inflammation, and/or infection of cellular subsets with 
different half-lives and homeostatic programming60,102,63 may contribute to the differences 
between viruses. We emphasize that SIVmac viruses have been robustly validated in 
large cohorts of RM. In addition, SIVmac infection results in more consistent viral 
kinetics and disease progression than SHIV infection, as a percentage of SHIV-infected 
RM typically spontaneously control infection and do not progress to AIDS. Thus, when 
selecting a virus for RM studies of HIV latency and cure, key differences in viral kinetics 
on and off cART as well as pathogenesis and related disease progression should be 
considered.  
One inherent limitation of many NHP experiments, including the study reported here, 
is the relatively short duration of both active viremia and cART administration.  In 
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contrast, the vast majority of people living with HIV and clinical trial participants are 
viremic for years prior to cART initiation, leading to a greater diversity of replicating and 
archived virus.  Individuals are then treated with suppressive cART for multiple years 
prior to reservoir evaluation, affording distinct reservoir dynamics with more time for the 
extinction of shorter-lived infected cells and homeostatic or antigen-driven clonal 
proliferation46. Given the importance of understanding what cells constitute the persistent 
reservoir and developing strategies to counter clonal expansion, this limitation of NHP is 
critical to recognize.  Experiments that evaluate the effects of years of cART therapy on 
SHIV and SIV-infected RM in the absence of an intervention, although logistically and 
financially challenging, could address many of these concerns. 
Despite relatively short times of virus replication prior to cART initiation in our two 
experiments, SHIV infection prior to and on cART reflects several characteristics of HIV-
1 infection, including viral diversity, polyclonal rebound, and infection of long-lived cells. 
Both SHIV.D and C-infected RM revealed significant pre-cART diversity, with a 
maximum within-animal pairwise diversity of between 0.7-2.5%, allowing for 
differentiation of distinct rebound virus populations.  In people living with HIV, 
recrudescent viremia after treatment interruption results from the systemic reactivation of 
multiple distinct latently infected cells47–50.  Similarly, TF SHIV rebound was largely 
polyclonal, with 7 of 8 cART-treated RM demonstrating multiple genetically distinct virus 
lineages replicating systemically within the first weeks of rebound, supporting a 
multifocal model of rebound in both systems.   
We found that the mean ca-DNA and ca-RNA measurements in chronic SHIV.D and 
SHIV.C-infected RM were comparable to chronically HIV-infected cART-naïve patients 
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(102-3 DNA copies/106 cells and 102-4 RNA copies/106 cells, respectively)106,107 . Ca-DNA 
and ca-RNA in SHIV.D and C-infected RM decreased modestly in the first three to six 
months following initiation of cART, consistent with the decay kinetics reported in studies 
of cART-suppressed PLWH34,107,108.  The magnitude of this decay reflects, at minimum, 
the clearance of plasma virus, productively infected activated T cells with a short half-life 
(less than two days), resting CD4 T cells with unintegrated virus, and likely shorter-lived 
monocyte and macrophage-lineage cells43,22. The persistence of ca-DNA and RNA and 
the rapid virus rebound seen after ATI indicates that the TF SHIV reservoir both persists 
with modest diminution in number and transcriptional activity of infected cells after three 
to six months of cART and has a slow decay rate on the order of months to years, as 
seen in HIV-1 infection. 
In SHIV.C-infected RM, we had a sufficient quantity of cells to characterize infection 
of multiple cellular subsets in LNMC and PBMC; low cell yields prevented similar 
analyses in SHIV.D-infected RM. We found that total resting memory CD4 T cells and 
Tcm in particular were productively infected at a mean frequency of 103-4 copies/106 cells 
throughout the course of the experiment (Figure 2.6D and F).  TCM have been identified 
as a major contributor to the latent reservoir in HIV+ cART-suppressed humans109.  We 
also found that TN, which given our sorting strategy includes memory stem T cells, were 
productively infected in all SHIV.C-infected RM, albeit at a lower magnitude than other 
subsets (Figure 2.6E). Our data suggest that TF SHIV infection leads to the 
establishment of a latent reservoir comprised of genetically diverse and long-lived cells, 
which persist through months of viral suppression and reactivate in the absence of 
cART.   
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We note some key differences between SHIV.D and SHIV.C-infected RM, 
suggesting that SHIV.C lacks some characteristics that are desirable for a robust model 
of HIV-1 latency.  Most importantly, SHIV.C-infected animals spontaneously controlled 
viremia below 103 c/ml post-rebound relatively frequently. In our study, rebound viremia 
rose to 103-7 c/ml within four weeks post-ATI in all TF SHIV-infected RM and then fell to a 
post-rebound set point, similar to SHIVs that demonstrate post-rebound virologic control 
in some RM56,57.  The emergence of adaptive (antibody24,6525,28,102 and CD8 T cell-
mediated23,110,111 immune responses have been shown to contribute to virologic control 
and exert significant selection pressure in both SIV and HIV-1.  Further, CD8 T cell 
responses were reported to be integral for bNab-mediated virologic control in two 
independent SHIV studies55,56.  In other TF SHIV experiments, we have found that CD8 
T cell depletion via administration of an anti-CD8 Ab leads to increases in plasma 
viremia in some, but not all, spontaneous controller RM by one to two log10 c/ml (data 
not shown), suggesting that CD8 T cells may contribute to TF SHIV virologic control, 
although off target effects of T cell depletion may also be a factor.  As an alternate 
explanation, SHIV.C infection may lead to lower levels of systemic virus replication post-
rebound than SHIV.D due to differences in intrinsic viral replicative capacity.  The pre-
cART VL was 103-4 c/ml in three of four SHIV.C-infected animals. The post-rebound set 
point VL was approximately one log10 c/ml lower and oscillated near the assay LOD of 
83 c/ml.  In parallel, we identified fewer distinct low-diversity lineages upon rebound in 
SHIV.C in comparison to SHIV.D, which may be attributable to the limited duration of 
viremia (16 weeks) prior to cART initiation and/or to the virus-host factors discussed 
above. Sequences from post-rebound time points in RM with control revealed that 
lineages present at first detectable rebound persisted over time in RM KM11 and KM65 
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despite periods of spontaneous viremic control, supporting the hypothesis that virus 
replication continued throughout this period at a level near our assay LOQ. At our 
sampling depth, we did not find evidence of clearance and subsequent replacement of 
the virus populations sampled at first detectable rebound in RM KM11 and KM65. 
Comparisons of rebound and pre-cART sequences did not identify specific motifs 
associated with virus control or persistence.  Many RM that went on to experience post-
rebound control generally had less virus diversity at rebound, but it is unclear whether 
the decreased virus diversity is a cause or an effect of enhanced immune-mediated virus 
control.   
In contrast, SHIV.D demonstrated many qualities that are desirable for a NHP model 
of HIV-1 persistence on cART. SHIV.D infection here and in previous studies84 
reproducibly led to high levels of systemic viremia over time. The viral dynamics and 
reservoir biology of SHIV.D before, during, and after cART suggest that SHIV.D is a 
promising NHP model for HIV-1 latency. SHIV.D encodes a well characterized and 
CCR5-tropic32 subtype D Env, representing an epidemiologically relevant30 and 
pathogenically important component of the HIV-1 pandemic.   Recognizing that subtype 
D viruses have been associated with rapid disease progression and frequent emergence 
of a CXCR4 or dual-tropic virus population, we analyzed sequences at the time point 
immediately preceding cART for genotypes predictive of CXCR4 tropism. Using the 
geno2pheno coreceptor algorithm, the majority of sequences in all RM were predicted to 
be equally or more CCR5-tropic than the TF SHIV (data not shown), suggesting a lack of 
progression to CXCR4 usage. Further, we did not see an enrichment of predicted 
CXCR4-tropic viruses in RM DE33 and EJ94, which exhibited higher set point VLs and 
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clinical disease progression.  Importantly, we previously tested isolates from SHIV.D-
infected RM that succumbed to AIDS using phenotypic co-receptor tropism assays and 
found that CCR5-tropism was retained84. 
Two of the six SHIV.D-infected animals had coincident VL rise and clinical 
deterioration. At necropsy, pathologic analysis revealed profound systemic CD4 T cell 
depletion and high viral burden in various lymphoid tissues in both RM and in PBMC 
from RM EJ94 (Figure 2.4A-C). Severe CD4 T cell depletion was identified in in gut-
associated lymphoid tissue (GALT) from both RM (Figure 2.4A); this tissue has been 
shown to harbor the largest number of CD4 T cells of any site in the body112. To date, TF 
SHIV pathogenesis has been documented in acute and early infection, where gut and 
lymphoid CD4 T cells are diminished, while peripheral CD4 T cells are relatively 
preserved85.  This degree of CD4 T cell depletion within one to two years of infection in 
two of six RM suggests rapid pathogenesis of SHIV.D infection.  
Our study has several limitations in addition to those described above.  First, one of 
six SHIV.D-infected RM (FT42) spontaneously controlled infection after 42 weeks of 
infection. Further, while all SHIV.C-infected RM rebounded, three of four did not maintain 
persistent plasma viremia following ATI. As delineated in Figure 2.8, virus control post-
rebound was associated with fewer variants and less diversity at rebound, which likely 
reflects the inability of the virus to replicate sufficiently to escape from host-control. The 
SHIV.C experiment also differed from the SHIV.D experiment in that the SHIV.C-infected 
RM were actively viremic for a shorter duration (16 weeks versus 37-85 weeks) and 
were inoculated with a stock that was 10-fold less infectious. These factors may have 
contributed to the frequency of post-control rebound in the SHIV.C-infected RM.  
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Altogether, the frequency of pre and post-cART viremic control of TF SHIVs, in particular 
SHIV.C-infected RM, is a limitation for their use in cure studies.   
Other study limitations include the sample size in both our SHIV.D and SHIV.C 
experiments, which was small (six RM and four RM per study, respectively), limiting the 
statistical power of our analyses. Additional studies in larger cohorts will be important to 
validate these findings. In addition, the duration of cART during our studies was limited 
to 24 weeks and therefore was insufficient to observe reservoir decay in longer lived 
cellular reservoirs, such as resting memory CD4 T cells, which have a half-life of months 
to years40. As we did not longitudinally sample tissues from the central nervous system 
and other possible anatomical reservoirs such as lymphoid tissues, which harbor the 
majority of CD4+ T cells in HIV-1-infected individuals, we were unable to characterize 
the viral reservoir dynamics at these sites43,113. Moreover, the quantity of cells collected 
after three to six months of cART in both SHIV.D and SHIV.C-infected RM were 
inadequate to conduct a more complete reservoir analysis, such as characterizing the 
genetic intactness and replication-competence of reservoir viruses using whole genome 
sequencing or viral outgrowth assays40.  
In summary, we have validated two novel TF SHIVs as relevant viruses in the RM 
model of HIV-1 latency.  The characteristics of SHIV.D.191859, and to a lesser extent, 
SHIV.C.CH848, during chronic infection, cART administration, and upon treatment 
interruption suggest that they are promising reagents for a SHIV model of HIV-1 latency 
and that they are suitable for studies of HIV-1 reservoir biology and pathogenesis.  Our 
findings demonstrate that the TF SHIV-macaque model has broad applications for 
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SHIVs encoding transmitted/founder (TF) HIV-1 Envs successfully infect rhesus 
macaques (RM) and confer consistent early viral kinetics. SHIV.CH505 encodes a TF 
clade C Env of significant interest, but it replicates inconsistently over time in a fraction 
of RM. Here, we develop and validate a minimally adapted SHIV.CH505 with enhanced 
replication. In two distinct cohorts of outbred SHIV.CH505-infected RM (n = 25 RM total), 
we identified a pattern of 4-7 virus mutations that arose and evolved towards fixation 
with greater frequency in RM with higher (>103 c/mL) vs. lower setpoint VLs using 
longitudinal sequencing. Two sequential limited in vivo passage experiments in which 
early SHIV.CH505-infected RM plasmas were intravenously inoculated into uninfected 
RM demonstrated that the signature mutation variants rapidly went to fixation and were 
associated with consistently high VLs (103-5 c/ml).  
A library of 15 SHIV.CH505 infectious molecular clones (IMC) containing the 
signature mutations alone or in combination were tested for replication in primary RM 
CD4 T cells. Results revealed that IMCs containing single and combination mutations 
replicated 2-4-fold and 3-46-fold better than the parental SHIV.CH505, respectively, but 
without a clearly dominant variant. An in vivo competition experiment of the 8 
combination clones in 3 outbred RM showed that a single IMC containing 5 mutations, 
termed 5MA, outcompeted in all 3 RM, comprising 76, 95, and 98% of all viruses at 4 
weeks post-infection. When tested in direct in vivo competition with the parental 
SHIV.CH505 in 4 RM, 5MA rapidly outcompeted the parental SHIV, representing 97-
99% of all viruses by 4 weeks post-infection. In all 7 RM in which IMC 5MA 
predominated, setpoint VLs were consistently high (between 103-5 c/ml). Neutralization 
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assays suggest that the 5MA IMC maintained its closed, native Env structure better than 
other clones that replicated well in vitro, but did not outcompete in vivo.   
5MA’s component mutations lie within or proximal to the CD4 and CCR5 binding 
sites, indicating that signature mutations confer possible effects on virus entry or are 
reversions to Group M consensus. In vitro entry assays confirmed that 5MA exhibited 
significantly increased entry into rhesus CD4 and CCR5-expressing cells compared to 
the parental SHIV.CH505.  In summary, we used a combination of in vivo passage and 
competition experiments and in vitro assessments to identify and validate a minimally 
adapted SHIV.CH505 with enhanced virus replication that may have broad applications 














The non-human primate (NHP) model employing rhesus macaques (RM) is an 
essential component of HIV research initiatives67,71,78,77.  Chimeric simian-human 
immunodeficiency viruses (SHIVs), which encode an HIV-1 envelope glycoprotein (Env) 
in the context of macaque-adapted simian immunodeficiency virus structural and 
regulatory elements, have been extensively used to study the role of HIV-1 Env in virus-
host interactions, transmission, and pathogenesis. SHIVs have particular importance as 
reagents in studies testing strategies that engage Env, such as broadly neutralizing 
antibodies (bNabs) and antibody-based vaccines55,57,56,79. 
One issue associated with SHIV development is that the majority of unadapted 
SHIVs do not yield persistent viremia over time67,71,76. Serial transfer, or passage of 
blood and tissues from a SHIV-infected to a naïve RM, has historically been successful 
in overcoming this limitation and conferring increased viral infectivity and pathogenicity. 
Passaged SHIVS, including the dual-tropic SHIV 89.667 and CCR5-tropic SHIVs 162P371 
and AD876, have been primarily used for evaluating vaccines and broadly neutralizing 
antibodies (bNAbs) in preclinical studies. Importantly, passaged SHIVs exhibit several 
key characteristics of HIV-1 infection, such as systemic CD4 T cell depletion and 
induction of adaptive immune responses71,76. 
A limitation of previous iterations of passaged SHIVs is that the encoded Envs 
were often sourced from individuals who had progressed to AIDS114,115, minimizing their 
relevance to transmitted/founder (TF) HIV isolates. Multiple reports suggest that TF 
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isolates have a unique signature compared to non-transmitted isolates, such as enriched 
Env content and increased interferon-beta resistance17,80. Further, passaged SHIVs 
exhibit substantial alteration of the parental HIV-1 Env sequence, thereby limiting their 
direct relevance to circulating HIV isolates78,13,71. An additional issue associated with 
previous iterations of SHIVs is that a subset of infected RM spontaneously control 
viremia to below 103 viral c/ml during chronic infection despite the increased 
pathogenicity and infectivity conferred by serial passage76,56 
 Recently, we reported the development of a novel strategy to generate designer 
SHIVs encoding native TF or primary Envs with Tier 2 neutralization sensitivity, hereafter 
referred to as TF SHIVs84. A study from Overbaugh and colleagues found that a singular 
residue (39)116 in rhesus CD4 domain 1 (D1) mediates functional differences in the ability 
of macaque and human CD4 molecules to bind HIV-1 Env. Env residue 375 in the Phe-
43 binding pocket, which is adjacent to the CD4 binding site, was found to be under 
strong selection pressure across primate lentiviruses, suggesting that mutagenesis of 
residue 375 could lead to increasing binding to rhesus CD4. Substitution of a single 
amino at Env position 375 resulted in the ability of various HIV-1 Envs to bind similarly to 
both rhesus and human CD473, enabling effective in vitro and in vivo infection of RM 
while preserving the protein conformation of the parental Env. TF SHIVs are CCR5-
tropic and consistently confer productive infection, high peak viremia, and desirable early 
viral kinetics84.   
Some TF SHIVs, however, replicate to lower set point VLs (VL) or are 
spontaneously controlled in a subset of RM in a manner similar to their predecessors. 
One such example is TF SHIV.CH505, which encodes a clade C TF Env and has been 
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used as a reagent for a NHP model of HIV-1 infection for numerous applications, 
including vaccine studies84,85,88,89,117. The CH505 virus was sampled from an African man 
who later developed CD4 binding site-directed broadly neutralizing antibodies (bnAbs) at 
around 1 year post-infection; an approach to elicit similar antibodies via vaccination in 
humans has been described118 and the Env-antibody co-evolution has been 
recapitulated in RM infected with SHIV.CH505119.  
The goal of our study was to use limited passage to identify a more fit version of 
this key reagent. We set out to use a reductive approach to serial passage, where we 
evaluated candidate infectious molecular clones (IMCs) in an in vivo competition setting, 
enabling the best replicating viral variant to outcompete in its host. 
Here, we performed a series of in vitro and in vivo studies to identify a minimum 
number of mutations that confer enhanced SHIV.CH505 kinetics with the goal of 
generating a robust reagent for the SHIV-macaque model of HIV-1 infection. We 
assessed the impact of candidate mutations on viral fitness in vivo and in vitro in primary 
rhesus CD4 T cells, as well as neutralization and entry assays.  Our results suggest that 
we have generated a minimally adapted SHIV.CH505 with a conserved Env 
conformation that enhances viral kinetics in vitro and in vivo. This novel reagent, termed 
SHIV.CH505.v2, has broad applications for a non-human primate model of HIV-1 
infection.  These results identify enhanced entry as the mechanism by which 




Materials and Methods 
Nonhuman Primates 
Indian-origin RMs were housed at Bioqual LLC according to the standards of the 
Association for Assessment and Accreditation of Laboratory Animal Care. All 
experiments were approved by the Penn Animal Care and Use Committee (ACUC).  All 
animals were tested and found to be negative for described SIV controller alleles Mamu-
A*01, B*08, and B*17.  Animals were sedated for SHIV inoculations, peripheral blood 
draws, and biopsies, as previously described84.  Whole blood from animals was 
processed using centrifugation as described in84. PBMCs were isolated using Ficoll-
Paque (GE Healthcare) gradient centrifugation. Plasma was clarified by centrifugation 
for 15 min at 3000 rpm, frozen, thawed, and then subject to viral RNA extraction as 
described below.  SHIV VL levels in plasma were determined by quantitative real-time 
reverse-transcription PCR of SIV RNA by the Duke University IQVAC Core Laboratory 
as previously described120. 
 
Construction and Characterization of Point and Combination SHIV.CH505 Clones  
SHIV.CH505 clones containing signature mutations in isolation were generated and 
viral stocks were made via transfection of 293T cells as described in 84. Briefly, amino 
acid change-conferring substitutions were placed into the SHIV.C.CH505.3C backbone 
using the Q5 Site-Directed Mutagenesis Kit (New England Biolabs). Primers were 
designed according to the NEBaseChanger tool (https://nebasechanger.neb.com).  All 
clones were sequenced in their entirety to verify that only desired mutations were 
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present in the constructs. 293T cells were transfected as described in 84.  Briefly, 6 ug of 
plasmid DNA and 18 ul of FuGENE 6 (Promega) transfection reagent were first added to 
a tube containing 0.5 mL of serum-free DMEM (Gibco) and then added to a pre-seeded 
Petri dish containing 3.6X106 293T cells in 10 mL of complete media (DMEM (Gibco), 
100 U/ml pen/strep (Gibco, and 10% FBS (Gibco)) that had incubated at 37C overnight. 
48 hours later, supernatants containing virus were spun at 3000 RPM for 8 minutes to 
pellet cellular debris and then aliquoted. 
The virion content of viral stocks was quantified using the p27Ag 96-well ELISA kit 
from ZeptoMetrix; the manufacturer’s instructions were followed with no alteration of the 
recommended protocol. Titration on TZM-bl cells was performed as described in 84; 
briefly, 15,000 cells were seeded in a flat-bottom 96-well tissue culture plate in 
quadruplicate and incubated at 37C overnight. The following day, fivefold dilutions of 
virus stock in sextuplet were plated, beginning with a virus stock dilution of 1:5 in 
complete cell media (DMEM (Gibco), 100 U/ml pen/strep (Gibco), 6% FBS (Gibco), and 
40 ug/ml DEAE-Dextran (Thermofisher)). After 48 hours of incubation at 37C, media was 
removed, cells were fixed by pipetting 100 ul of fixing solution in each well (500 ml PBS, 
4 ml glutaraldehyde, 11 ml formaldehyde). After 10 minutes, cells were washed 3X with 
PBS and 100 ul of X-gal staining solution was placed into each well. After 3 hours, cells 
were washed 3X with PBS and the number of blue cells in each well was counted using 
an automatic counter. The average number of blue cells in two consecutive dilutions 
across all 4 quadruplicates was determined and standardized to the input virus volume; 
the final titer was the mean of 2 consecutive titers. 
73 
 
Stocks of SHIV.CH505 clones containing signature mutations in combination 
were generated as described in 84.  Briefly, 8 candidate Envs containing variations of 
signature mutations were synthesized by Synbio Technologies and were cloned into the 
SHIV.3C backbone using the BsmBI restriction sites at the 5’ and 3’ end of the CH505 
Env cassette and then ligated together using T4 ligase (NEB). 8 plasmids encoding full-
length SHIV.CH505 combination clones were used to transfect 293T cells as described 
above and in 84. Infectivity on TZM-bl cells and virion content was determined as 
described above. The infectivity of CH505 combination clone stocks ranged between 
1.18X10-3 and 9.00X10-4 IU/particle, respectively, as determined on TZM-bl cells. 
 
Generation of CH505.5MA and TF Barcoded Stocks (Study 5) 
Barcoded stocks of SHIV.CH505.5MA and SHIV.CH505.TF were generated as 
described in 84,121.  Briefly, the CH505.TF and CH505.5MA Envs were cloned into a 
SHIV.3C backbone containing NotI at the barcode insertion site using the BsmBI 
restriction sites at the 5’ and 3’ end of the Env cassette and SHIV.3C backbone and then 
ligated together using T4 ligase (NEB). The barcode inserts consisted of single stranded 
forward and reverse barcoded templates consisting of 10 random bases each. The 
forward and reverse barcode primers were heated to 95°C and then cooled at a rate of 
1.5°C/min to enable annealing. SHIV.CH505.TF.barcoded (BC) and 
SHIV.CH505.5MA.BC were digested with NotI. DNA was purified and the digested 
viruses and primer dimers were ligated at 16°C overnight. The ligated, barcoded viruses 
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were transformed into Stbl2 cells. The plasmid library was DNA extracted and barcodes 
were sequenced via the Illumina platform. Stocks were made as described above.  
Infectivity on TZM-bl and virion content was determined as described above. The 
infectivity of SHIV.CH505.TF.BC and SHIV.CH505.5MA.BC stocks on TZM-bl cells were 
1.86 and 4.3X10-4 IU/particle, respectively.  To assess the infectivity of SHIV.CH505.TF 
and SHIV.CH505.5MA on primary rhesus CD4 T cells, activated cells were plated at a 
density of 3×105 cells/well in 96-well flat-bottom tissue culture plates in complete primary 
cell culture media (RPMI (Gibco) with 15% FBS (Gibco), 100 U/mL penicillin–
streptomycin (Gibco), 30 U/ml IL-2, and 40 µg/mL DEAE–dextran (Thermofisher)). 
Fivefold dilutions of virus stock in sextuplet were plated, beginning with a virus stock 
dilution of 1:5; the virus stock in each well was diluted to a total of 60 ul of complete 
primary cell culture media as described above. The virus mixture was incubated for 3 h 
at 37°C.  Complete media was added to bring the total volume to 0.25 mL in each well, 
after which the plate was incubated at 37°C. p27 antigen measurements were made at 
day 4 and TCID50 was calculated by using the Reed Muench method. The infectivity of 
viral stocks was determined via titration on TZM-bl cells as described above and in 84.   
The infectivity on primary rhesus CD4 T cells ranged between 1.83X10-4 and 5.32X10-5 
IU/particle, which is similar to other TF SHIVs84. These stocks were used for the 
experiments described in Study 5; no barcode sequencing of RM samples, however, 





Study 3 Inoculum 
For passage 1, RM 5695 was intravenously inoculated with a mixture of plasma 
containing 200 ul from each of the following RM and timepoints: RM 6069 and 6070 at 
10 and 20 WPI and RM 6072 at 4, 10 and 20 WPI. For passage 2, RM 5181 was 
intravenously inoculated with 200 ul of plasma from RM 5695 at the following timepoints: 
4, 8, 16, and 24 WPI. 
 
Study 4 Inoculum 
The Study 4 inoculum was prepared by adding 10 ng of each of 8 candidate 
CH505 combination clones, with the stock containing 80 ng total per animal. The stock 
was then diluted in complete media (RPMI (Gibco) with 15% fetal bovine serum (FBS, 
Gibco), 100 U/mL penicillin–streptomycin (Gibco)) to a volume of 1 mL per animal. RM 
T646, 5593, and 150250 were inoculated with the CH505adapted stock mixture. 
 
Study 5 Inoculum 
The Study 5 inoculum was prepared by combining 2 stocks: SHIV.CH505.5MA 
and SHIV.CH505.TF. 2 inocula were prepared, with inoculum 1 (30 ng total) containing 
15 ng and the inoculum 2 (300 ng total) containing 150 ng of each variant, respectively. 
Virus stocks were prepared using the same medium as in Study 4. The 300 ng stock 
mixture was sequenced via single genome sequencing as described below and diluted 
1:10 to make the 30 ng virus stock mixture; each inoculum vial was diluted to a volume 
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of 1 ml per animal. RM T276 and T277 were inoculated with 30 ng and RM T278 and 
T279 were inoculated with 300 ng of the Study 5 inoculum, respectively. 
 
Viral Single Genome Sequencing 
Single-genome full-length gp160 env sequences were generated as described in 
84.  Briefly, 20,000 viral RNA copies were extracted from plasma virus using the Qiagen 
BioRobot EZ1 Workstation with EZ1 Virus Mini Kit v2.0 (Qiagen).  Eluted vRNA was 
subsequently used as a template for cDNA synthesis and reverse-transcribed using the 
reverse primer SHIV.Env.R1 (5′- TACCCCTACCAAGTCATCA-3′) and SuperScript III 
reverse transcriptase (Invitrogen Life Technologies). cDNA was serially diluted in a 96-
well plate (Applied Biosystems) to identify the dilution at which <30% of wells contained 
PCR amplicons of the correct size.  The SHIV gp160 env genome was amplified via 
nested PCR with primers as follows: first round forward primer SHIV.Env.F1 (5′- 
CGAATGGCTAAACAGAACA-3′), second round forward primer SHIV.Env.F2 
(CTACCAAGGGAGCTGATTTTC), first round reverse primer SHIV.Env.R1 (5′- 
TACCCCTACCAAGTCATCA-3′), and second round reverse primer SHIV.Env.R2 5’-
TATTTTGTTTTCTGTATGCT-3’). PCR conditions were used as follows for the first 
round of nested PCR: 94°C, 2 min; 37x [94°C, 20 sec; 55°C, 30 sec; 68°C, 3 min 30 
sec]; 68°C, 10 min. For the second round of nested PCR, the PCR conditions were as 
follows: 94°C, 2 min; 42x [94°C, 20 sec; 54°C, 30 sec; 68°C, 3 min 30 sec]; 68°C, 10 
min. Amplicons were sequenced via the MiSeq platform (Illumina). Raw reads were 
aligned to the SHIV.CH505 reference using Geneious R9. Sequences that contained 
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mixed bases at a frequency of >25% per nucleotide position were excluded from further 
analysis.   
Sequences from plasma virus from RM 6069, 6070, and 6072 (Study 1) were 
generated at 4, 10 and 20 WPI. Sequences from RM in Study 2 were generated at 52 
WPI. Due to the limited number of available sequences, which was attributable to low VL 
at the time of sampling in a number of RM, an 100% penetrance threshold was used to 
identify virus populations that had one or more non-synonymous AA substitutions in Env. 
Sequences were re-examined using 50% as the penetrance threshold for non-
synonymous AA substitutions, which resulted in similar findings (data not shown). 
Sequences from plasma virus from RM 5695 (Study 3) were generated at 2, 4, 12, 16, 
24, and 48 WPI. Sequences from plasma virus from RM 5181 (Study 3) were generated 
at 2, 8, 12, and 24 WPI.  
 
Viral Deep Sequencing 
Approximately 103-105 viral RNA copies were extracted from plasma and cDNA 
was generated as described above and in 84. The volume of cDNA required to sample 
102-3 individual copies was determined and used as the input for bulk PCR amplification, 
with amount of plasma vRNA copies in the initial sample being the limiting factor. Nested 
bulk PCR conditions were used as follows for the first round of nested PCR: 94°C, 2 min; 
37x [94°C, 20 sec; 50°C, 30 sec; 68°C, 1 min]; 68°C, 10 min. For the second round of 
nested PCR, the PCR conditions were as follows: 94°C, 2 min; 42x [94°C, 20 sec; 68°C, 
30 sec; 68°C, 1 min]; 68°C, 10 min. The primers used were as follows: first round 
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forward primer CH505adapted F1 5’-TGCTCCAGCTGGTTATGCG-3’, second round 
forward primer CH505adapted F2 5’-TCGTCGGCAGCGTCAGA 
TGTGTATAAGAGACAGTGTCAGCACAGTACAATGTACACA-3’, first round reverse 
primer CH505adapted R1 5’-TGTTATGTTTCCTGCAATGGG-3’ and second round 
reverse primer CH505adapted R2 5′-GTCTCGTGGGCTCGGAGATGTGTA 
TAAGAGACAGATTGCTCGTCCCACCTCCTG-3′.  
Bulk PCR reaction products were multiplexed and sequenced via the MiSeq 
platform (Ilumina). The frequency of variants most similar to the 8 candidate 
CH505adapted clones were determined using a software analysis pipeline, incorporating 
open source software with custom scripts written in python, bash, and R.  Raw reads 
were aligned to the SHIV.C.CH505 T/F reference sequence using bowtie2 with default 
parameters.    Reads that had more than 7 mismatches to the reference genome 
were excluded from downstream analysis, to allow for reads with all 6 mutations 
identified upstream (V255I, N279D, K302N, Y330H, N334S, H417R) plus one additional 
mismatch.  Each remaining read's bowtie alignment was used to extract the nucleotides 
at the six variant locations.  The 6 nucleotides of interest were used to classify each 
read, and each sample was condensed to a summary of how many reads had each 
particular combination of nucleotides/variants.  Frequencies of variants were calculated 
against the number of reads passing all filters. 
 
Rhesus CD4 T Cell Isolation and Activation 
Rhesus CD4 T cells were isolated as described in 84 . Briefly, rhesus PBMC were 
combined with magnetic CD4 MicroBeads (Miltenyi Biotec) and processed according to 
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manufacturer’s instructions. Antibiotin MACSiBead particles loaded with biotinylated anti-
CD2, CD28, and CD3 antibodies (T-cell activation/expansion kit from Miltenyi Biotec) 
were combined with isolated rhesus CD4 T cells as described by the manufacturer. The 
isolated CD4+ cells were cultured in complete growth medium (RPMI with 15% fetal 
bovine serum (Hyclone), 100 U/mL penicillin–streptomycin (Gibco), and 30 U/mL IL-2 
(Prometheus Laboratories) for 5-6 days.  
 
SHIV Replication in Primary Rhesus CD4 T Cells. 
SHIV infection of primary rhesus CD4 T cells were performed as described in 84.  
Each SHIV variant was normalized to 300 ng of input virus per well and combined with 
2X106 rhCD4 T cells in complete RPMI 1640 growth medium containing 40 µg/mL 
DEAE–dextran and 30 U/ml IL-2 to a total volume of 1 mL per well in a 24 well-plate.  
The cell and virus mixtures were incubated at 37 °C in 5% CO2 for 4 h and subsequently 
washed 3 times with 10 mL of complete RPMI growth medium without DEAE-dextran 
and IL2. Cell and virus mixtures were each resuspended in 1 mL of complete RPMI1640 
growth medium and 30 U/ml IL2 in 24-well plates and cultured for 9 days.  Supernatants 
were collected on days 0, 3, 6, and 9 for p27 antigen measurement. For the summary 
graphs shown in Figure 3.5, the first timepoint at which the replication of TF.CH505 was 
>5 or 10 ng/ml for point and combination clone experiments, respectively, was used, 
reasoning that this timepoint was early enough to 1) allow for comparison between 
independent experiments given differences in time to peak replication, 2) mitigate the 
confounding factors of decreased cell viability and depletion of available target cells that 
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occur towards of the tail end (~d9+) of the experiment, and 3) capture differences in viral 
replication rates that perhaps would be most apparent at earlier timepoints. 
 
TZM-bl Neutralization Assay 
 TZM-bl neutralization assays were performed as described in 84. Briefly, TZM-bl 
cells were seeded at 10,000 cells per well. After 24 hours, selected antibodies (Ab) were 
serially diluted 5-fold and mixed with 4,000 IU of virus stock as measured on TZM-bl 
cells. Antibody-virus mixtures were co-incubated for 1 h and then added in triplicate to 
pre-seeded TZM-bl cells. After 48 hours, cells were simultaneously lysed and mixed with 
luciferase substrate via addition of Bright-Glo (Promega). Background-corrected 
luciferase activity for each sample was determined as described in 84; IC50 values were 
calculated using the variable slope function in Prism (v7.0). All monoclonal antibodies 
(PG121, VRC01, 3BNC117, PGT145, 4E10, 17B, 3869) were obtained from the NIH 
AIDS Reagent Program. 
 
ZB5 Entry Assay 
 ZB5 cells were propagated and infected as described in84. Briefly, cells were 
propagated in complete growth medium containing DMEM (Gibco) + 10% FBS (Gibco) + 
100 u/ul pen/strep (Gibco); medium was supplemented with 5 μg/mL blasticidin (Thermo 
Fisher Scientific) to select for rhCCR5 expression and 5 μg/mL puromycin (Sigma-
Aldrich) to select for cells expressing rhCD4. 
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The ZB5 entry assay was performed in triplicate. Cells were seeded at 1×104 per 
well in 100 ul of complete media in 96-well plates and incubated overnight. Virus stock 
dilutions were made to final concentrations in complete DMEM + 40 μg/mL DEAE–
dextran to achieve 0.5 ng p27 antigen/well. Day 1 medium was removed and cells were 
incubated at 37 °C with the virus inoculum diluted in complete growth medium for 48h. 
Cells were lysed with Bright-Glo (Promega) 48 h post-infection, and RLUs were 
measured on a Luminoskan Ascent luminometer (Thermofisher).  
 
Results 
Identification of a signature of enhanced SHIV.CH505 viral kinetics 
The determinants of viral setpoint in HIV-1 infection are multifactorial, balancing 
virus fitness and host immune pressures.  Within the SHIV-macaque model, and 
SHIV.CH505 specifically, the viral determinants of replication fitness are likely complex 
and context-dependent. To this end, we set out to identify a common mutational 
signature associated with enhanced viral fitness by comparing virus evolution in 
SHIV.CH505-infected RM with higher versus lower VLs over the first six months of 
infection. 
SHIV.CH505 infection results in a range of set point VLs; across 4 published 
studies, 21% of SHIV.CH505-infected RM (n=33) spontaneously controlled plasma 
viremia to around or below 102 c/ml by 12 weeks post-infection85,88,89. Of the remaining 
RM, 52% exhibited VLs of 102-3 c/ml at the same time point, while 27% exhibited higher 
VLs of 104-5 c/ml. 3 RM from this aggregate cohort (6069, 6070, and 6072, Study 1)84 
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that exhibited high VL (104-6 c/ml) for 36-40 weeks were analyzed (Figure 3.1) 2 RM in 
this cohort were euthanized at 36-40 WPI due to progression to AIDS. The remaining 
RM 6072 maintained persistent viremia of 103-4 c/ml for over 52 weeks. 
Single genome sequences (SGS) of gp160 env were generated from longitudinal 
plasma samples (4, 10 and 20 WPI) for the 3 RM (Figure 3.1A, total number of 
sequences = 287, median number of sequences per animal time point = 41). SGS of 
plasma virus limits in vitro recombination, allows linkage across the amplified region, and 
accurately characterizes the relative frequency of the diverse, circulating quasispecies15.  
While mutations that arise in one RM are often a result of adaptation to a host-specific 
immune response, mutations that are shared across multiple outbred RM are likely to 
reflect a virus-specific benefit.  A limited number of shared mutations were common to 
the 3 RM over the first 5 months of infection. Thus, majority mutations that were present 
in 50% of sequences at 20 weeks post-infection (WPI) from all 3 RM were collated. 2 
mutations, N334S and H417R, arose early in all animals, representing a majority of 
sequences in all RM by week 10 and increasing to 77-100% penetrance by 20 WPI.  4 
additional mutations (N130D, N279D, K302N, and Y330H) arose later, in the presence 
of N334S and H417R. By 20 WPI, mutations K302N, Y330H, N334S, and H417R were 
present in 77-100% of sequences in all 3 RM, with the exception of K302N (51% 
prevalence) in RM 6072. Thus, 6 conserved sites of selection pressure in gp160 env 
(130, 279, 302, 330, 334, and 417) were identified in all 3 RM with higher VL (Figure 




Confirmation of a mutational signature of sustained SHIV.CH505 viremia  
Next, we examined virus sequences from an orthogonal cohort of 45 
SHIV.C.CH505-infected RM (Study 2) to assess if the mutational signature described in 
Study 1 was common across multiple cohorts of RM. In this study, 28 RM were 
vaccinated with a CH505-based Env DNA vaccine and 17 control RM received either an 
adjuvant or no intervention118,117. All RM were subsequently challenged with the 
autologous SHIV.CH505; 40 of 45 RM became infected. Vaccine administration had a 
modest effect (~1 log10) on VL at several early timepoints (2-9 WPI); after 9 WPI, 
however, no significant difference in VL among the groups was detected.  Plasma virus 
from 22 of 40 infected RM was sequenced via SGS at 52 WPI to mitigate the effect of 
these early differences in VL and enable combining all RM into a single group. 5 of these 
22 RM maintained high (>104 c/ml) set point VLs at 32 WPI, while the remaining 17 RM 
had lower VLs, ranging from <50 to 103 c/ml; this timepoint was selected due to lack of 
consistent sampling across all RM at later timepoints (Figure 3.2A). We then assessed if 
the prevalence of signature mutations was enhanced in high versus low VL RM 
(summarized in Figure 3.2B, which describes mutations that appeared with 100% 
penetrance in each RM). 
Similar to the Study 1 RM, a higher frequency of the identified signature 
mutations K302N, Y330H, N334S, and H417R was identified in high vs. low VL RM at 
this time point. These 4 substitutions were 17-56% more prevalent in high vs. low VL 
RM, depending on mutation (Figure 3.2B). The prevalence of mutations N130D and 
N279D, which were identified in Study 1, was modestly increased in high versus low VL 
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RM (20% versus 6%, Figure 3.2B). Thus, a similar genetic signature of sustained set 
point viremia was identified in a second cohort of RM. 
 
SHIV.CH505 passage results in enhanced viral kinetics 
Limited in vivo passage, or serial transfer of blood or infected tissues from an 
infected to naïve RM, has been used historically to improve the viral kinetics of SHIVs 
that initially replicated poorly67,71,76. We performed a limited passage experiment in 2 RM 
(Study 3) using plasmas from early infection from 3 previously described RM (Study 1) to 
test whether the identified signature mutations would outcompete wildtype virus, 
determine the kinetics of the shifts in viral populations, and determine if earlier evolution 
of signature mutations led to consistently higher VLs. The first animal, RM 5695 was 
inoculated with a mixture of high VL plasma from early time points (4, 10 and 20 WPI, 
see methods) from the 3 RM described in Study 1 (Figure 3.3A); we termed this 
experiment passage 1 (P1). The inoculum contained a greater percentage of variants 
from earlier timepoints due to higher VL at the time of sampling, with 7% and 69% of 
variants originating from 4 and 10 WPI, respectively; plasma virus at 4 WPI was similar 
to CH505.TF in terms of sequence (Figure 3.1A). 
RM 5695 exhibited high peak viremia (105-6 c/ml), maintained persistent viremia 
(103-4 c/ml) for over a year and was euthanized at 64 WPI due to progression to AIDS 
(Figure 3.3A). Longitudinal env gp160 SGS were generated using plasma from 2 to 48 
WPI (Figure 3.3B, total number of sequences = 450, median number of sequences per 
animal = 42).  
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At 2 WPI, the only 2 signature mutations sampled in most or all of the sequences 
in RM 5695 were N334S and H417R, similar to what was sampled in the inoculum RM at 
10 WPI; this finding was unsurprising given that viruses from this timepoint were 
overrepresented in the inoculum. Sequences at 4 WPI revealed strong evidence for a 
selection bottleneck between 2 and 4 WPI; by this time, 100% of sequences contained 
the K302N, Y330H, N334S, and H417R signature mutations (Figure 3.3B). 
A slightly different pattern of sequence evolution arose in RM 5695 over time in 
comparison to Studies 1 and 2. By 12 WPI, 100% of circulating plasma viruses in RM 
5695 contained the 6 signature mutations identified in Study 1 and 2 (N130D, N279D, 
K302N, Y330H, N334S, H417R) in addition to a novel mutation, V255I (62% prevalence, 
Figure 3.3B and C). All signature mutations persisted, and at 24 WPI, 94-100% of all 
circulating virus contained all 6 previously identified signature mutations. The frequency 
of V255I also increased at this timepoint (77% prevalence). Interestingly, V255I was 
present in only a minority (44%) of sequences from Study 1 RM 6069 at 20 WPI and was 
not found in any other sequences from Study 1 and 2 RM (Figures 3.1 and 3.2). By 48 
WPI, only 1 signature mutation, N130D, substantially decreased in frequency in RM 
5695 (43% prevalence, Figure 3.3B and C). 
The second passage animal, RM 5181, was inoculated with plasma from RM 
5695 from early time points (4-24 WPI, Figure 3.3A). The passage 2 (P2) inoculum was 
both highly enriched for all 6 signature mutations and genetically diverse, with the vast 
majority of variants being divergent from wild type SHIV.CH505. As with RM 5695, serial 
passage led to enhanced longitudinal viral kinetics in this RM. RM 5181 exhibited slightly 
higher VLs than RM 5695 at each timepoint after 12 WPI (2-15-fold difference), and 
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exhibited high set point viremia (104-5 c/ml) for over a year (Figure 3.3A), at which point 
RM 5181 developed symptoms consistent with AIDS and was euthanized. 
In RM 5181, by 2 WPI, 93-100% of plasma virus variants contained the 6 
signature mutations; in addition, most contained the V255I mutation (72% prevalence, 
Figure 3.3B and C), which rapidly went to complete fixation by 8 WPI.  Thus, all 6 
signature mutations achieved fixation early and remained at fixation in both passage 
animals.  
 
Signature mutations are located in sites predicted to interact with rhesus CD4 and 
CCR5 
To better understand the putative roles of signature mutations, all 7 residues (130, 
255, 279, 302, 330, 334, 417) were modeled onto the BG505 SOSIP Env monomer 
using PyMOL (Figure 3.4). Of these, all residues except for 130 were predicted to be 
located in or adjacent to the rhesus CD4 and CCR5 binding sites. Env residue 130 is 
located at the N-terminus of the V1 loop near the apex of the Env trimer and is not 
proximal to described CCR5 and CD4 binding sites (Figure 3.4). In addition, N130D was 
no longer present in the majority of sequences in P1 RM 5695 by 48 WPI and was not 
selected for in the cohort of high VL RM examined in Study 2; due to these reasons, it 
was excluded from further consideration. 
The remaining 6 signature mutation residues were found to be located in the gp120 
bridging sheet (255, located in C284 and 417122, located in V4), which links the inner and 
outer domains of gp120 Env upon binding to CD4, in the CD4 binding site (279)123, and 
87 
 
at the N and C-termini of V3 (302 and Y330, respectively)66. Residue 334, which is 
located in C3, is also located adjacent to the CD4 binding site66.  Some signature 
mutations (K302N, Y330H, N334S) encode AAs that are highly conserved (70-96%66) 
across all HIV-1 isolates; mutagenesis of the remaining 3 Env residues (255124, 279125, 
417126,127) in the context of HIV-1 IMCs modulated binding and/or entry into CD4 and 
CCR5-expressing cells in several studies. 
 
In vitro replication of SHIV.CH505 clones 
To determine the contribution of individual signature mutations to virus 
replication, full-length SHIV.CH505 IMCs containing each of 6 signature mutations in 
isolation were generated and shown to be infectious in vitro. The single mutation clones 
were used to infect primary rhesus CD4 T cells in at least 3 independent experiments 
(Figure 3.5A). Figure 3.5A shows a representative experiment testing all single mutant 
clones against the TF. With the exception of V255I, all of the signature mutations in 
isolation conferred minimal benefit, with a consistent non-significant increase in 
replication over wildtype SHIV.CH505 (median = 1.8 to 3.3-fold increase in p27, p=1, 
Dunnett’s multiple comparisons test) across 2-3 independent experiments, Figure 3.5A. 
The IMC containing V255I, in contrast, consistently exhibited significantly worse 
replication than the parental TF virus (median = 29.4-fold decrease in p27, p<0.0001, 
Dunnett’s multiple comparisons test, Figure 3.5A).  
IMCs encompassing combinations of the 6 signature mutations were generated 
to test their effect on viral replication. Clones were generated using a novel TF SHIV 
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backbone, 3C, which contains deletions in the tat and gp41 env reading frames that 
were selected for in vivo in RM infected with various TF SHIVs. The 3C backbone 
demonstrated a modest fitness advantage in vitro compared to the dCT backbone 
previously used for TF SHIV design84 (data not shown). 
Clones were named according to the number of signature mutations present 
compared to the TF (see Figure 3.5B legend). Several clones (4MA, 5MA, and 5MB) 
encoded combinations of mutations seen in vivo (Figures 3.1, 3.2, and 3.3). The 
remaining clones (4MB, 3MA-3MD) encoded individual reversions to assess the 
contribution of a particular signature mutation to viral fitness in the context of other 
mutations. Figure 3.5B shows a representative experiment testing the combination 
clones against the TF. By 3 DPI, enhanced replication compared to the TF was 
detectable, with all combination clones except for 3MA exhibiting a 3.0-16.6-fold 
increase in p27 antigen. The increased levels of replication persisted through later 
timepoints, though some replication curves appear dampened by loss of activated target 
cells.  
When tested in 2-3 independent experiments of mixed/single RM donor CD4 T 
cells, almost all of the CH505 combination clones replicated substantially better than the 
parental TF SHIV (median = 8.1 to 17.1-fold increase in p27 across 2-3 independent 
experiments, Figure 3.5B), with the exception of clone 3MA, which replicated similarly to 
the TF (median = 0.2-fold decrease in p27). Although 3 combination clones exhibited 
significant increases in replicative capacity compared to the TF across all 3 experiments 
(5MB, 3MB, and 3MD, p<0.05, Dunnett’s multiple comparisons test), a clearly dominant 
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clone amongst those tested in any individual experiment was not identified, as the best 
replicating virus varied depending on rhesus donor. 
While mutations in isolation did not significantly affect virus replication in vitro, 
combination clones replicated robustly (Figure 3.5A and B), suggesting that there is an 
additive or synergistic effect of signature mutations on viral replicative capacity. Of note, 
although the V255I signature mutation was consistently deleterious to viral replication 
when introduced in isolation to the parental TF Env, when added in the context of the 
other mutations that arose simultaneously in vivo in Study 3 (K302N, Y330H, N334S, 
H417R), the resultant clone 5MA, demonstrated enhanced virus replication (Figure 3.5A 
and B). 
 
In vivo competition of candidate SHIV.CH505 combination clones  
The sequence analysis and vitro studies described earlier, while informative, are 
not able to determine which multiple competing factors are most important for viral 
fitness in vivo; these factors include, but are not limited to, ability to efficiently enter 
rhesus cells, intrinsic replicative capacity, and ability to evade autologous neutralizing 
antibody (nAb) and other innate and adaptive immune responses. We performed an in 
vivo competition experiment using a lower-dose inoculum to enable competition between 
viral variants during critical timepoints in early infection.  We defined this period as 1-4 
WPI, as the effects of replication differences would most evident at the earliest 
timepoints post-infection when the virus is expanding exponentially with ample cellular 
targets; in HIV-1 infection, it takes approximately 4 weeks for the nadir VL to be reached 
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in acutely HIV-infected individuals reflecting an exhaustion of target cells and resolution 
of peak viremia128 . Further, using early timepoints as a point of comparison would 
minimize the effect of adaptive immune responses on virus selection as much as 
possible. A second goal of this experiment was to determine the extent to which in vitro 
studies of fitness (Figure 3.5) predict in vivo viral fitness. 
Three outbred RM were infected with 10 ng of each of 8 candidate CH505 clones 
(Figure 3.6A, left) and followed longitudinally.  All animals became productively infected 
with peak VL ranging from 104-5 c/ml (Figure 3.6B).  Of note, as sampling was only 
performed at 1, 2, and 4 WPI, it is likely that the peak VL measurement was not captured 
with this sampling strategy. In all 3 RM, viremia was maintained above 102 c/ml through 
48 WPI, with set point VLs ranging from 103-5 c/ml between 32 and 48 WPI.  
 To identify with great sensitivity which signature mutant best competed in vivo, a 
deep sequencing strategy with amplicons including the 500 nt region in Env 
encompassing all candidate mutations was employed using the Ilumina platform (Figure 
3.6A). Sequences from plasma virus at 1, 2, and 4 WPI were generated (Figure 3.6A). 
As our deep sequencing strategy requires a bulk amplification step, we performed 
limited SGS for selected early time points (W1, W2) in parallel to determine the 
frequency of in vitro versus in vivo recombinants; we did not identify any in vivo 
recombinants using SGS (data not shown). Sequences from 1 WPI demonstrated that all 
8 variants been transmitted and led to productive replication to all 3 RM (Figure 3.6A). 
The frequencies of other CH505 variants began to wane at 2 WPI, and by 4 WPI, 
variants containing 5MA signature mutations dramatically outcompeted all others, 




CH505 signature mutations alter Env conformation 
 Viruses that circulate in HIV+ individuals encode Envs are predominantly Tier 2 
and have been adapted to evade nAbs via several mechanisms, including 
conformational masking, glycan shielding and epitope variation, leading to a closed Env 
that is not easily accessible to the autologous Ab response52. Autologous antibodies 
overwhelmingly target immunodominant regions of Env such as V3 and gp41 that 
typically elicit poorly or non-neutralizing antibodies129,130.  
Many laboratory-adapted viruses, which replicate well in vitro, exhibit altered and 
non-native Env conformation as a result of the lack of Ab pressure in vitro, differentiating 
them from primary HIV-1 isolates52. We assessed if and how these mutations altered the 
closed nature of the primary CH505 Env due to signature mutations being located in or 
proximal to the rhCD4 and CCR5 binding sites. We tested the sensitivity of the panel of 
8 combination clones to monoclonal (m)Abs 3869, which targets linear V3 peptides and 
preferentially binds Tier 1 viruses131 and 17B, which preferentially binds open CD4-
bound Envs that express a non-native conformation132 (Figure 3.7A and B).  
Clones 4MA, 5MA, and 5MB exhibited combinations of mutations seen in vivo, while 
the remaining clones (4MB, 3MA-3MD) were missing at least one mutation that emerged 
in vivo in all 3 RM studies by design. While most combination clones did not exhibit 
substantially altered Env conformation (<50% neutralization of virus at a maximum mAb 
concentration of 10 mg/ml), there were a few exceptions, namely clones 3MB and 3MC, 
which contained combinations of mutations that were only seen in Studies 1-3 in the 
92 
 
context of additional mutations. Clones 3MB and 3MC had increased sensitivity to both 
3869 and 17B compared to the TF (70-81 versus 0% neutralization, respectively, Figure 
3.7A and B), implying that they bear more resemblance to non-Tier 2 or lab-adapted 
HIV-1 isolates than the other CH505 combination clones. 
Clone 4MA appeared to be modestly more sensitive to both 17B and 3869, although 
the mean neutralization percentage across 4 independent experiments did not reach the 
50% threshold. In summary, these data suggest that introduction of signature mutations 
into the CH505 Env can lead to altered protein conformation. These results also suggest 
that encoding combinations of mutations observed in vivo in the context of the primary 
CH505 Env results in a closed Env conformation. Taken together, these results suggest 
that 5MA emerged as the leading candidate in vivo due to its combination of increased 
intrinsic replicative capacity and closed Env conformation. These results also provide a 
rationale as to why combination clones that encode a more open Env conformation 
despite demonstrating robust in vitro replication (3MB, 3MC) were not selected for in 
vivo. 
 
In vivo competition of CH505adapted versus CH505.TF 
To confirm and quantify the in vivo fitness of the variant, 5MA, which had 
outcompeted all other CH505 variants in Study 4, we performed a more direct in vivo 
competition experiment between this variant and the parental wildtype (WT) 
SHIV.CH505 (Study 5). Four RM were inoculated with a virus mixture containing equal 
amounts of TF and 5MA viruses as determined via p27 antigen measurement. 2 RM 
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(T276 and T277) were intravenously challenged with a lower dose inoculum (15 ng of 
each variant) and 2 RM (T278 and T279) were intravenously challenged with a higher 
dose inoculum (150 ng of each variant, Figure 3.8A, left). All RM became productively 
infected with peak VL of 105-6 c/ml at 1.5-2 WPI in all 4 RM (Figure 3.8B).  In all 3 RM, 
viremia was maintained above 103 c/ml through 24 WPI, with set point VLs ranging from 
103-5 c/ml at the most recent timepoint (24 WPI). 
Deep sequencing over the region between the 5 signature mutations revealed 
that both variants were transmitted to all 4 RM (Figure 3.8A, right). At 1 WPI, variants 
containing 5MA mutations made up 47-79% in all 4 RM; the proportion of viruses 
containing 5MA mutations increased to 57-88% by 2 WPI in all animals. At 4 WPI, 
variants containing 5MA signature mutations dramatically outcompeted the TF, 
comprising 93-95% of all circulating viruses in all 4 RM.  
Interestingly, differences in VL between RM that were challenged with high 
versus low VL became detectable beginning at 4 WPI. The 2 RM that received the low-
dose inoculum exhibited VL that were 9-27-fold higher (mean) at 4-24 WPI than in RM 
that received the higher dose inoculum. Further, the proportion of variants containing 
5MA mutations was modestly larger in low-dose (64-79%) versus high-dose inoculum 
(47-60%) RM at 1 WPI.  
 
CH505.TF and 5MA have conserved Env conformations 
Given that Studies 4 and 5 had identified 5MA as a leading candidate, we 
performed a more thorough characterization of potential differences in antigenic 
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conformation in 5MA versus TF.CH505 (Table 3.1). The antigenic conformation of 5MA 
was shown to be similar, although not quite identical (<4-fold difference in IC50) 
compared to CH505.TF when tested for neutralization sensitivity to a panel of bNAbs 
targeting conserved Env epitopes, including the CD4 binding site (VRC01, 3BNC117), 
the V2 apex (PGT145), and the gp120/gp41 interface/membrane-proximate external 
region (4E10, Table 3.1). The exception to this result was 5MA’s increased sensitivity to 
PGT121, which targets the V3 glycan supersite. The N334S mutation present in clone 
5MA introduces an N-linked glycosylation site (NLGS) at residue 332 and subsequently 
enables recognition by PGT121. 
A few minor, but not unexpected, differences in sensitivity to CD4 and V2 bNAbs, 
however, were noted. 5MA demonstrated modestly decreased (3-4-fold) sensitivity to 
CD4 bNabs and modestly increased (3-fold) sensitivity to the V2 apex bNAb PGT145. A 
previous study found that Env residue 255 substitution results in decreased binding of 
HIV-1 isolates to huCD4 and increased sensitivity to V2 apex bNAbs124; thus, the V255I 
mutation likely mediates the differential sensitivity of 5MA to both types of bNAbs. 
Notably, both 5MA and TF Envs were completely resistant to mAbs 3869 and 17B 
(Figure 5), suggesting that 5MA has a similarly closed Env conformation. 
 
Replication of CH505 clone 5MA in isolation 
 To characterize the in vivo properties and fitness of clone 5MA in isolation, 4 
outbred RM (Study 6) were IV infected with a virus stock containing 340 ng of 5MA and 
followed longitudinally (Figure 3.9). Peak VLs ranged between 106-7 c/ml, while set point 
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VLs ranged between 103-5 c/ml at 12 WPI, with no incidence of spontaneous viremic 
control. This experiment is ongoing. 
 
CH505 clones containing signature mutations have differential entry into cells 
expressing rhCD4 and CCR5 
To assess the mechanism of enhanced replication, we asked whether more 
facile entry was the predominant cause.  This is biologically plausible, as mutations lie 
within or proximal to CD4 and coreceptor (CoR) binding sites. To assess the contribution 
of signature mutations to differences in cell entry, ZB5 cells, which stably express rhesus 
CD4 and CCR584 and encode a luciferase reporter, were infected with the 14 point and 
combination mutation clones described in Figure 3.5. An additional clone with the N130D 
mutation in isolation was included as a comparator.  
 Clones containing signature mutations in isolation were tested against the TF; 
percent entry was normalized to the TF (shown as a dotted line in Figure 3.10A and B). 
4 signature mutations (N130D, Y330H, N334S, H417R) appeared to minimally affect 
entry into ZB5 cells in isolation (Figure 3.10A). 2 mutations (V255I and K302N) were 
significantly deleterious to viral entry (59 and 49% decrease in entry, respectively, 
p<0.05, Dunnett’s multiple comparisons test, Figure 3.10A). 
Combination clones were also tested against the TF (Figure 10B). 2 clones (5MA 
and 3MD) demonstrated significantly enhanced entry compared to the TF (>64% 
increase, p<0.0001, Dunnett’s multiple comparisons test). A third clone (5MB) also 
demonstrated significantly increased entry (>45% increase, p<0.001, Dunnett’s multiple 
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comparisons test), albeit to a lesser extent.  These findings suggest that entry is a 
significant contributor to the enhanced replication seen in vitro and in vivo for 5MA. 
These results, however, do not completely explain why 5MA emerged as the leading 
candidate in vivo given that 5MB and 3MD also enter rhesus cells efficiently, reinforcing 










Figures and Tables 
Mutation 
Frequency N130D N279D K302N Y330H N334S H417R
6072
W10 46% 0% 0% 0% 100% 81%
W20 54% 85% 51% 98% 100% 95%
6069
W10 0% 0% 0% 7% 100% 51%
W20 68% 100% 100% 100% 100% 100%
6070
W10 71% 0% 0% 0% 100% 92%
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Figure 3.1. Identification of a signature of enhanced SHIV.CH505 VL kinetics 
(Study 1). A. Amino acid highlighter plots showing single genome env sequences from 
SHIV.CH505-infected RM 6069, 6070, and 6072 (Study 1) at 4, 10, and 20 WPI. Non-
synonymous substitutions compared to the TF sequence are indicated by a red line and 
deletions are shown as a black line. Each horizontal line shows one single genome 
sequence. 6 signature mutations arose de novo in all 3 RM by 20 WPI. N130D is shown 
in blue, while N279D, K302N, Y330H, N334S and H417R, are indicated in purple. B. 














N130D N279D K302N Y330H N334S H417R
High VL RM 20% 20% 80% 80% 100% 80%
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Figure 3.2. Confirmation of a signature of enhanced SHIV.CH505 viral kinetics 
(Study 2). A. VL kinetics of SHIV.CH505-infected RM in Study 2. Weeks post-infection 
are shown on the x-axis. Plasma VL in c/ml is shown on the y-axis. Geometric means of 
RM with high (>104 c/ml) or low (<103 c/ml) VL at 32 WPI are shown in bold. B. 
Frequency of signature mutations in sequences at 52 WPI in high vs. low VL RM using a 





























































Frequency N130D V255I N279D K302N Y330H N334S H417R
5695
W2 37% 3% 11% 8% 8% 100% 90%
W12 100% 19% 100% 100% 100% 100% 100%
W24 94% 77% 98% 100% 100% 100% 100%
W48 43% 74% 100% 100% 100% 100% 100%
5181
W2 93% 72% 97% 100% 100% 100% 100%
W12 100% 99% 100% 100% 100% 100% 100%
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Figure 3.3. CH505 passage 1 and 2 (Study 3). A, left. RM 5695 was inoculated with a 
mixture of early plasmas from RM 6069, 6070, and 6072. RM 5181 was inoculated with 
a mixture of early plasmas from RM 5181. A, right. Viral kinetics for RM 5695 (top) and 
5181 (bottom). Euthanasia due to AIDS progression is indicated by a black cross. B. 
Amino acid highlighter plots showing longitudinal env sequences from P1 and P2 RM 
5695 and 5181. 5 signature Env mutations (N279D, K302N, Y330H, N334S and H417R) 
that were previously identified in Figure 3.1 and 3.2 are indicated in purple. N130D is 
indicated in blue. V255I, a novel signature mutation, is shown in green. C. Summary 
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Figure 3.4. Structural modeling of CH505 Env with signature mutations. Signature 
mutations were modeled onto the BG505 SOSIP Env monomer using PyMOL. Variable 
















































































































































































Figure 3.5. In vitro replication of CH505 clones. A, left. Replication of clones 
containing signature point mutations in primary rhesus CD4 T cells. Plots indicate 
representative experiments repeated 2-3 times. Day post-infection is indicated on the x 
axis. Viral replication (shown as levels of ng/ml) is indicated on the y axis. A, right. Box-
and-whiskers plot showing relative fold-change in p27 compared to matched TF values 
for point mutants across all experiments. TF.CH505 is indicated by the dotted line at y=1 
for comparison. B, left. Replication of clones containing multiple signature mutations in 
primary rhesus CD4 T cells. Day post-infection is indicated on the x axis. Viral replication 
(shown as levels of ng/ml) is indicated on the y axis. B, right. Box-and-whiskers plot 
showing relative fold-change in p27 compared to matched TF values for combination 
clones across all experiments. TF.CH505 is indicated by the dotted line at y=1 for 
comparison. * indicates p<0.05, *** indicates p<0.001, **** indicates p<0.0001. Statistical 









































Figure 3.6. In vivo competition of candidate CH505 clones (Study 4). A, left. Deep 
sequencing results of the virus stock for the CH505 clone competition experiment (Study 
4) are shown on the left. RM were inoculated with 80 ng of virus stock (10 ng from each 
of 8 CH505 clones). A, right. Longitudinal deep sequencing results for Study 4 RM are 
shown on the right. Sequence depth was >95,000 sequences for each sample. B. Viral 
kinetics of Study 4 RM. Week post-infection is indicated on the x-axis. Plasma VL in c/ml 




Clone TF 5MA 5MB 4MA 4MB 3MA 3MB 3MC 3MD
IC50 NR NR NR NR NR NR 0.03 0.41 NR
MPI 0 0 0 34 7 7 81 74 0
3869
Clone TF 5MA 5MB 4MA 4MB 3MA 3MB 3MC 3MD
IC50 NR NR NR NR NR NR 0.60 2.0 NR
MPI 0 0 16 40 0 7 77 70 23
75-100 MPI = red
50-74 MPI = orange
25-49 MPI = green























































Figure 3.7. CH505 signature mutations alter Env conformation. A. Neutralization of 
CH505 clones in TZM-bl cells by mAbs 17B (left) and 3869 (right). mAb concentration is 
indicated in ug/ml on the x-axis. Percent infectivity compared to the mean measurement 
in virus-only wells, which is set to 100%, is indicated on the y-axis. Y-axis values indicate 
mean and standard error across 2-4 independent experiments performed in triplicate. 
IC50 is indicated by the dashed line. B. Summary table of results presented in A. Values 
indicating 50% inhibitory concentration (IC50) and maximum percent inhibition (MPI), or 
the percentage of virus neutralized by 17B or 3869 at the maximum mAb concentration 
























RM T276 (30 ng)
RM T278 (300 ng)
RM T277 (30 ng)
RM T279 (300 ng)
Figure 3.8. CH505 clone 5MA outcompetes the TF in vivo (Study 5). A. Deep 
sequencing results of the virus stock for Study 5 are shown on the left. RM were 
inoculated with either 30 or 300 ng of virus stock containing equal amounts of 5MA and 
TF.CH505 virus stocks. Longitudinal deep sequencing results for Study 5 RM are shown 
on the right. Sequence depth was >100,000 sequences for each sample. B. Viral 
kinetics of Study 5 RM. Week post-infection is indicated on the x-axis. Plasma VL in c/ml 
is indicated on the y-axis. 
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75-100 MPI = red
50-74 MPI = orange
25-49 MPI = green
NR = not reached
MPI
Clone PGT145 PGT121 VRC01 3BNC117 4E10
5MA 89 100 100 100 50
TF 83 0 97 97 50
IC50
Clone PGT145 PGT121 VRC01 3BNC117 4E10
5MA 0.18 0.04 0.51 0.18 10
TF 0.57 NR 0.18 0.05 10
 
Table 3.1. CH505.TF and 5MA have conserved Env conformations. A. MPI and IC50 
values for mAbs PGT145, PGT121, VRC01, 3BNC117, and 4E10 when tested against 
































Figure 3.9. Clone 5MA viremia over time (Study 6). A. RM were inoculated with 340 
ng of clone 5MA. Weeks post-infection are indicated on the x-axis. Plasma VL in c/ml is 









































































Figure 3.10. CH505 clone entry into ZB5 cells. Entry of CH505 clones into ZB5 cells, 
which express rhesus CD4 and CCR5, are shown normalized to entry of TF.CH505 
(100%, dotted line). Data summarizes 3 independent experiments performed in triplicate. 
A. Normalized entry of clones with signature mutations in isolation. B. Normalized entry 
of combination clones. * indicates p<0.05, ** indicates p<0.01, *** indicates p<0.001, **** 









Given the historical success of using serial passage to develop and improve SHIVs, 
we utilized this method to augment the viral kinetics of SHIV.CH505 to enhance its 
suitability for a SHIV-macaque model of HIV-1 infection. Several factors necessary for 
both in vitro and in vivo replication and persistence, such as efficiency of entry into cells 
expressing rhesus CD4 and CCR5, evasion of the host immune response, and 
enhancement of infectivity in vitro and in vivo, must be balanced in order for a virus to 
become adapted to its host. In addition, a suitable virus would need to encode an Env 
with a closed and conformationally masked conformation to aid in successful host 
immune evasion. 
Here, we describe the generation of a minimally adapted SHIV.CH505 encoding 5 
mutations. We used the framework underlying serial passage to generate an vivo 
competition experiment where the most fit viral variant would outcompete in its host; this 
work is the first to do so, to our knowledge. First, we identified a genetic signature of 4-6 
mutations in gp120 Env that were associated with sustained set point viremia in 8 
SHIV.CH505-infected RM in 2 independent studies (Figures 3.1 and 3.2). In the setting 
of a limited passage experiment in 2 RM, a similar mutational signature was identified; 
these mutations arose and went to fixation earlier than in a setting where they had to 
arise de novo and were associated with enhanced VL kinetics over time (Figure 3.3). An 
additional signature mutation (V255I) was identified in both Study 3 RM (Figure 3.3). 
Structural modeling (Figure 3.4) suggested that 6 of 7 identified signature mutations 
are located in sites that interact with or are adjacent to human and/or rhesus CD4 and 
CCR5-binding sites. It is important to note that there are some structural and functional 
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differences between the rhesus and human CD4 and CCR5 molecules116,133. Functional 
mapping studies of all non-synonymous substitutions in rhesus versus human CD4, 
however, have revealed that a single mutation at the N-terminus in D1 of rhesus CD4, 
which binds gp120 Env, mediates differential binding to HIV-1 Env116, as the remaining 
11 substitutions in D1 had minimal effects on HIV-1 Env binding. As Env 375 substitution 
results in similar binding and entry into rhesus cells, it is likely that the modest sequence 
variation between rhesus and human CD4 does not result in significant functional 
differences between the 2 molecules84. A previous report found that HIV-1 Envs bind to 
rhesus and human CCR5 in a conserved manner, likely on account of high sequence 
conservation (98%) between both molecules133. Further, the 3 non-synonymous 
substitutions in rhesus versus human CCR5 do not restrict viral entry of primary HIV-1 
isolates, as tested viruses were able to comparably infect cells that express CCR5 from 
either species133. 
N130D, an additional signature mutation which was excluded from further analysis 
due to the reasons described earlier, most likely arose due to early autologous nAb 
responses targeting the V1 region in Env, which has been previously reported in HIV-1 
infection and was shown to be conserved in SHIV.CH505-infected macaques134,135,119. 
Further, N130D arose in the CH505 source patient at 52 weeks post-infection118. 
X-ray crystallography, cryo-EM, and mutagenesis studies summarized here shed 
further light into the putative role of each mutation. N302 is highly conserved across 96% 
of HIV-1 isolates66. Further, a recent cryo-EM study of the gp120 Env ectodomain in 
complex with human CD4 and CCR5 identified N302 as a CCR5 contact residue122. The 
impact of Y330H on HIV-1 or SHIV viral fitness is currently unknown. H330, however, is 
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conserved in 70% of HIV-1 isolates66, as is S334 (75% conservation)66. As a result, 
K302N, Y330H and N334S are likely viral fitness reversions to Group M consensus. 
Multiple mutagenesis studies have identified residue 417 as a mediator of binding and 
entry into CD4-expressing target cells126,127. Of note, the residue of choice in HIV-1 
appears to be P, with 85% conservation at this site across all sequenced global isolates 
(LANL 2018 Compendium). It is therefore likely that H417R is a either a rhesus CD4-
specific adaptation or a result of the conserved nAb response in both the CH505 source 
patient and SHIV.CH505-infected RM and incidentally modulates viral fitness119.  
 Previous structural modeling found that Env residue 255 is located within 4Å of the 
CD4 binding site84. A recent report124 found that the V255M substitution, which is 
structurally similar to the V255I substitution, altered the Env conformation of several HIV-
1 isolates by reducing the ability of Env to bind CD4, resulting in increased sensitivity to 
apex-targeting bNAbs that preferentially recognize closed Envs. Residue 279 is a known 
CD4 contact residue123; in HIV-1 isolates, the N279D mutation conferred resistance to 
CD4 binding site-directed Abs125.  
A recent study found that Env mutation A281T/V frequently arises in the setting of in 
vivo SHIV adaptation in RM and confers a modest virus fitness advantage in vitro136. In 
the parental SHIV.CH505, the amino acid at residue 281 is the “optimized” V. Notably, 
the inverse substitution (V281A) arose in one Study 1 RM, 6070, with 17% prevalence at 
20 WPI, but not in any other Study 1, 2, or 3 RM; in these RM, the T and V alleles were 
retained at residue 281. 
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CH505 clones containing signature mutations in isolation demonstrated a marked 
increase in intrinsic replicative capacity in comparison to the TF in primary rhesus CD4 T 
cells (Figure 3.5A). 7 of 8 candidate clones containing combinations of signature 
mutations replicated substantially more robustly than the TF in vitro (3.5B). Clone 5MA, 
which contains 5 AA changes compared to CH505.TF, emerged as the front runner in 
both competition in vivo studies (Study 4 and 5), rapidly outcompeting other candidate 
combination clones (Figure 3.7) as well as CH505.TF by 4 WPI (Figure 3.8). The 
dramatic in vivo selection of 5MA is likely attributable to several factors, including 
increased in vitro infectivity in primary rhesus CD4 T cells (Figure 3.5), retention of 
native Env conformation, and Tier 2 neutralization sensitivity (Figure 3.6 and Table 3.1). 
5MA was one of several engineered clones that encompassed a set of signature 
mutations that were maintained in vivo (Figures 3.3, 3.6, and 3.8). The enhanced 
infectivity of 5MA in vitro is mediated at least in part by enhanced entry into rhesus CD4 
and CCR5-expressing cells compared to the TF (Figure 3.10). Accordingly, the infectivity 
per particle ratio of 5MA was found to be 2.31-fold and 3.53-fold greater when titrated on 
TZM-bl and primary rhesus CD4 T cells, respectively, compared to the TF (data not 
shown).  
Taken together, results from in vitro studies were supportive, although not entirely 
predictive, of in vivo studies, as combination clones 5MB and 3MD also demonstrated 
enhanced in vitro replication (Figure 3.5), significantly enhanced entry into ZB5 cells 
(Figure 3.10), and retained closed Env conformation (Figure 3.7), but nonetheless did 
not outcompete other clones in vivo at key early time points in Study 4 (Figure 3.6). 
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In vitro studies suggest that V255I and N279D contribute to enhanced viral 
replicative capacity in vitro (Figure 3.5B) and modulate Env protein conformation in a 
similar manner when compared to clone 4MA (Figure 3.7). Clone 4MA contains 4 of 5 
substitutions present in clone 5MA and encoded a modestly more open Env 
conformation (Figure 3.6). Notably, despite detection of all 6 CH505 combination clones 
in all Study 4 RM at 1 WPI, which presented ample opportunity for in vivo recombination, 
a combination clone with all 6 signature mutations (V255I, N279D, K302N, Y330H, 
N334S, H417R) was not selected for. These results suggest that substitutions V255I and 
N279D have potentially redundant roles in the context of other signature mutations and 
that 5MA, which encodes the V255I mutation, appears to be more fit in vivo. 
The V255I mutation likely arose later in Study 3 RM 5695 and was not selected for in 
Study 1 and 2 RM due to its poor intrinsic replicative capacity in isolation (Figure 3.5A). 
Based on these data, it is likely that V255I requires compensatory fitness mutations (i.e. 
K302N, Y330H, N334S, H417R) to arise in vivo. A virus engineered to encode these 4 
mutations in addition to V255I, however, is sufficiently fit to replicate robustly in vitro 
(Figure 3.5B) and outcompete all other tested CH505 variants in vivo (Figure 3.6 and 8). 
V255I did not arise in the CH505 source patient118, suggesting that it may be a rhesus 
CD4-specific adaptation. 
The contribution of the signature mutations described here to SHIV.CH505 viral 
fitness may not necessarily be generalizable to other SHIVs. Nonetheless, this study 
serves as a conceptual framework suitable for adapting other SHIVs that replicate 
suboptimally in RM. The approach delineated in this study echoes previous work 
described by Sodroski and colleagues67,68, which utilized a similar approach to augment 
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the pathogenesis of SHIV 89.6 and subsequently dissect the mechanisms responsible 
for enhanced infectivity and pathogenesis.  
These results suggest that the role of mutations that conferred enhanced fitness in 
this context can be broadly defined as falling into 2 distinct subtypes: 1) increased 
efficiency of utilization of CD4 and CCR5 via entry or other mechanisms or 2) fitness 
reversions to Group M consensus. These results, like others68,84 pinpoint efficient viral 
entry as a mediator of increased fitness in rhesus-adapted SHIVs, a particularly 
important consideration given that the structural and regulatory elements of SHIVs 
outside of Env are SIVmac-derived and therefore already are sufficiently adapted to the 
rhesus macaque. Viral entry, however, is likely not the only contributing factor, as it does 
not explain why 5MB or 3MD were not selected for in vivo despite also showing 
increased entry into rhesus cells. 
We acknowledge several limitations associated with our studies. First, the effect of 
CH505 signature mutations on other HIV-1 Envs was not evaluated. As a result, it is 
possible that signature mutations are context-dependent and cannot be used to augment 
other SHIVs.  Alternatively, signature mutations may be generally advantageous for viral 
fitness in SHIVs, which would require additional investigation.  
In addition, the temporality of host immune pressures following infection, which have 
been shown to emerge as early as 1.5-4 WPI in HIV27,28 and SHIV85 infection, preclude 
our ability to decisively state that variants with signature mutations were selected for in 
Studies 1-5 solely due to a viral fitness advantage, as it is possible that host neutralizing 
antibody and/or CD8 T cell responses exerted significant selection pressure on the virus 
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population. As discussed earlier, since viral fitness can be considered to encompass 
both intrinsic viral replicative capacity as well as the ability of the virus to escape 
adaptive immune pressures in its host, we do not find this caveat to be a significant 
confounding factor of this study. 
There are several additional limitations associated with the in vivo passage studies 
described in Figure 3.3, including the use of plasma-derived virus to infect RM 5695 and 
5181, as antibodies in plasma, if still viable, could potentially neutralize virus from earlier 
time points prior to inoculation. A second limitation is that RM 5695 and 5181 were 
infected with a viral swarm as opposed to a single IMC, which could have contributed to 
enhanced viral kinetics due to increased viral diversity at the time of virus acquisition. 
This increased inoculum diversity could have contributed to attenuated adaptive immune 
responses in these RM, resulting in the unusually enhanced VL seen in Study 3 RM. 
Nonetheless, given that we identified a similar mutational signature in 10 other RM in 2 
additional studies (Figures 3.1 and 3.2), it is likely that these factors did not significantly 
confound our results. 
We employed a deep sequencing approach to generate the results described in 
Figures 3.6 and 3.8 due to the expense and labor involved in SGS as well as the 
increased sensitivity of deep sequencing in detecting minority variants. One major 
limitation of deep sequencing, however, is that it precludes our ability to differentiate 
between in vitro and in vivo error. Accordingly, we detected recombinant variants even in 
the Study 4 inoculum, despite sequencing every CH505 clone that comprised the 
inoculum in its entirety and not identifying any recombinants. Further, we stratified the 
recombinants according to numbers of mutations present and found that the vast 
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majority of recombinants contained 4 of 5 signature mutations and were missing either 
V255I and H417R, suggesting that these sites were inclusive of common break points. 
This finding is inconsistent with a pattern of random in vitro recombination. Limited SGS 
(n = 9-30 sequences), which prevents in vitro recombination altogether, was performed 
at 1 and 2 WPI for all Study 4 RM and 2 of 4 Study 5 RM; no recombinants were 
identified in any of the sequenced samples, adding further evidence that most, if not all, 
of the recombination observed in the samples sequenced in Figures 3.6 and 3.8 was 
artefactual in nature (data not shown). These limitations, however, are unlikely to 
significantly affect the interpretation of the results presented here. 
  Our results suggest that clone 5MA, which we have termed SHIV.CH505.v2, 
retains the very properties that make it valuable, including conserved antigenicity and 
Tier 2 neutralization sensitivity, yet confers enhanced longitudinal enhanced viral 
kinetics, resulting in a promising model for HIV-1 latency and cure research.  
Applications for this novel reagent include both vaccine and bNAb-based studies as well 
as latency and cure studies. Efforts to assess the suitability of SHIV.CH505.v2 for 
latency and cure research via measurement of VL kinetics and reservoir before, during, 
and after cART administration, are ongoing (Figure 3.9). We conclude that 
SHIV.CH505.v2 has potential as an important new NHP reagent with broad applications 






CHAPTER 4: CONCLUSIONS AND FUTURE DIRECTIONS 
Summary 
A robust simian-human immunodeficiency virus (SHIV)-macaque model of 
latency is critical to investigate eradicative and suppressive strategies that target HIV-1 
Env.  TF SHIVs are engineered to mitigate issues associated with previous iterations of 
SHIVs. Most importantly, TF SHIVs encode HIV Envs that are biologically relevant to 
and representative of isolates that are transmitted to and circulate in PLWH.  
Prior to this work, the reservoir biology and pathogenesis of infection in RM both 
off and on cART had not been characterized for any iteration of SHIV, including those 
developed by our group. Here, for the first time, I evaluated TF SHIVs for their suitability 
for HIV-1 latency and cure research (Chapter 2). In this chapter, I found that in general, 
TF SHIVs recapitulate key aspects of HIV-1 reservoir biology and persistence, with 
several caveats. The findings described in Chapter 2 expand the field’s knowledge of the 
benefits and limitations of SHIVs as a model for HIV latency and cure research and 
enable the design of more rigorous preclinical studies, where results could be more 
easily translatable to clinical trials. 
The theory of serial passage builds upon studies examining the factors 
associated with cross-species transmission, in which adaptive and innate immune 
pressures, including intrinsic antiviral restriction factors, antibodies, and CD8 T cell 
responses, among others, exert significant selective pressure upon a pathogen 
introduced into a novel host. Thus, a pathogen must be able to evade all of these 
immune defenses to adapt fully to a novel host. Serial passage, which involves infecting 
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RM with diverse SHIV variants and enabling the host to choose the most fit virus, has 
been historically successful in improving SHIV kinetics. The work described in Chapter 3 
is the first to utilize an approach that distills this concept to a more reductive form. In 
Chapter 3, I describe how the concept of serial passage can be repurposed to engineer 
IMCs that are representative of viral mutations associated with fitness that are selected 
for in vivo in multiple RM, including in a limited passage setting. 
I generated 8 SHIV.CH505 infectious molecular clones (IMCs) that were 
generally representative of the virus populations circulating in SHIV.CH505-infected RM 
and were shown to have desirable characteristics for a NHP model of HIV-1 infection in 
vitro. Out of these 8 IMCs, 5MA alone dramatically outcompeted others by 4 weeks post-
infection in 7 outbred RM. I found that the enhanced fitness in vitro and in vivo of the 
leading candidate clone, 5MA, was at least partly explained by its ability enter target 
cells more efficiently than TF.CH505 (Chapter 3).   
Throughout the history of SHIV development, the rationale behind spontaneous 
viremic control of SHIVs to below 102-3 c/ml is of great interest, but poorly elucidated. 
Although the work presented here does not definitively identify the mechanisms 
responsible for spontaneous control, it suggests that shifting the SHIV-host balance to 
the side of the virus by developing SHIVs with enhanced replicative capacity can 
mitigate this issue. The mechanisms underpinning the enhanced persistence of 
SHIV.CH505.v2 are likely mediated by a combination of enhanced entry, binding to 
target cell receptor and coreceptor, and/or fusogenicity, consistent with the mechanistic 
studies of SHIV 89.6 described by Sodroski and colleagues67,68. This work is the first to 
use an analogous approach to dissect the mechanisms responsible for the enhanced 
119 
 
fitness of a CCR5-tropic SHIV. Thus, the studies presented here could provide an 
experimental framework for augmenting other promising SHIVs that demonstrate 
variable persistence in RM. 
 
Future Directions 
Reservoir biology and viral persistence in TF SHIV-infected RM 
 Given that there are an extensive number of well-powered SIVmac studies, it will 
be important to validate the findings observed for TF SHIVs 191859 and CH848 in larger 
cohorts of RM to better assist investigators deciding between the SHIV and SIVmac 
models. Higher-powered studies will be particularly important given the high incidence of 
spontaneous control (3 of 4 animals) in the SHIV.CH848-infected RM described in 
Chapter 2. Further, given that the duration of cART in humans is often years to 
decades40, it will be important to repeat these studies in a setting where longer term 
cART (>24 weeks) can be administered. Long-term administration of cART would allow 
the opportunity to potentially identify reservoir decay in longer lived cellular reservoirs 
such as resting memory CD4 T cells using methods such as quantitative viral outgrowth 
assays (QVOA)40 or quantification of intact proviral DNA (IPDA)137 which have been 
robustly validated in HIV-1 infection40. In addition, quantification of ca-DNA and RNA in 
tissues from the central nervous system43 and other possible anatomical reservoirs in 
HIV-1 infection will be necessary to validate the robustness of this model for HIV latency 
and cure research.  
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Further, it will be important to plan studies that result in recovery of enough viable 
PBMC and LNMC to conduct QVOAs. This would enable quantification of the number of 
ca-DNA and ca-RNA+ cells that harbor replication-competent vs. incompetent virus. In 
addition, we did not sample lymphoid tissues from the SHIV.CH848-infected RM 
described in Chapter 3. It would have perhaps been informative to assess if the lack of 
persistent viremia in 3 of 4 SHIV.CH848-infected RM post-rebound was linked to 
decreased reservoir seeding in lymphoid tissues compared to RM KK54, which 
maintained persistent post-rebound viremia. At least one line of evidence suggests that 
this question merits further investigation: the magnitude of virus dissemination, as 
assessed by ca-DNA and RNA quantification, was substantially higher in tissues from 
SHIV.D-infected progressor RM EJ94 and DE33 in comparison to RM FT42, which 
spontaneously controlled viremia at 42 WPI and did not progress to AIDS (Figure 2.4),  
In addition, due to an inadequate number of viable cells, we were not able to sort 
LNMC into all T cell subsets, including Tscm, Tem, etc. and were not able to sort LNMC 
from SHIV.D-infected RM by subset. It would be helpful to characterize the LNMC and 
PBMC populations in RM infected with other TF SHIVs, as the characterization of T cell 
subsets in 4 RM infected with a single TF SHIV is inadequate to fully characterize SHIV 
reservoir biology and persistence in both PBMC and tissues. 
 
Defining the mechanisms associated with enhanced SHIV.CH505.v2 viral fitness 
 Given the role of signature mutations in SHIV.CH505.v2 viral fitness, it will helpful 
to fully probe the mechanisms by which signature mutations confer enhanced in vivo and 
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in vitro fitness. The work presented here addresses the contribution of signature 
mutations to viral entry. This was assessed via a single-round entry and infection assay 
with ZB5 cells, which stably express rhesus CD4 and CCR5. The ZB5 assay identified 
entry as an important component of replication differences associated with some, but not 
all, mutations.  This assay, however, does not address myriad other mechanisms that 
could be responsible for the increased infectivity of candidate SHIV.CH505 clones. 
Future work should examine other factors that can modulate enhanced viral fitness, 
including syncytium-forming abilities as described by Sodroski and colleagues68 in the 
context of SHIV 89.6 clone KB9. A clone with enhanced fusogenicity would be predicted 
to result in greater cytopathic effects, which could be tested via a controlled syncytium 
formation assay where Env-expressing SHIV.CH505 clones would be co-cultured with 
target CEMx174 cells sourced from the NIH AIDS Reagent Program. The number of 
cells that have formed syncytia could be counted using microscopy after 6 hours, which 
would help determine if signature mutations affect viral fusogenicity.  
Further, it would be worthwhile to test whether signature mutations affect affinity 
for and binding to rhesus CD4. This could be determined using TZM-bl neutralization 
assays, where soluble rhesus e-CD4-Ig could be serially diluted and tested against 
SHIV.CH505 clones instead of bNAbs or plasma as described in 84. In addition, it would 
be helpful to assess if introduction of signature mutations alter CH505 Env affinity and 
binding to the rhesus CCR5 molecule, which could be assessed using titration of soluble 
rhesus CCR5 or the titration of a CCR5 inhibitor, such as maraviroc, which binds to 
human as well as rhesus CCR5, using the modified TZM-bl neutralization assay 
described above138. All of these possibilities will need to be evaluated in order to fully 
122 
 
dissect the mechanisms responsible for the increased replication of 5MA in vivo and in 
vitro, in addition to enhanced entry. 
 
Validating SHIV.CH505.v2 for latency and cure research 
 While a pilot study that aims to validate SHIV.CH505.v2, for latency and cure 
research is ongoing, it will be important to 1) carefully characterize SHIV.CH505.v2 
reservoir biology and immunopathogenesis in these RM and 2) compare and contrast 
this virus with its predecessor, SHIV.CH505.TF, as well as other TF SHIVs and HIV-1. 
First, extensively sampling both PBMC and lymphoid tissues and assessing the extent of 
CD4 T cell depletion and virus dissemination as determined via ca-DNA and RNA 
quantification upon necropsy would be necessary. Second, sequencing the virus 
population using SGS at pre-cART and post-ATI timepoints and comparing viral diversity 
measures, including pairwise diversity and clonality, to other TF SHIVs and HIV-1 would 
be beneficial. Further, given an appropriate quantity of viable cells, it would be useful to 
assess what percentage of the viral reservoir in both blood and tissues is replication 
competent, which could be determined via QVOA or IPDA. Finally, the detection of viral 
rebound post-ATI would serve as the most definitive proof that a persistent viral reservoir 
is seeded during SHIV.CH505.v2 infection, thus validating this model for HIV-1 latency 




Testing therapeutics, cure strategies, and vaccines in TF SHIV-infected RM 
 TF SHIVs are highly suitable for evaluation of Env-targeting agents, as they 
encode Envs that are more relevant to TF and circulating variants than any previous 
iteration of SHIV. TF SHIVs are as sensitive to available bNAbs as their parental HIV-1 
isolates; further, the antigenic profiles of TF SHIVs have been extensively characterized, 
in contrast to some SHIVs currently in use. SHIV 162P3 is resistant to many classes of 
bNAbs including those targeting various conserved epitopes, such as V1V2, MPER, and 
the CD4 binding site, among others73. The antigenic conformation of SHIV AD8EO has 
not been extensively characterized. However, SHIV AD8E0 is far more resistant to a 
number of bNAbs than the parental AD8 Env139.  
A study by Boyd et al.139 determined that adapting SHIVs AD8EO and 162P3 to 
macaque CD4 resulted in substantial conformational changes, exposing epitopes that 
are masked in the parental Envs and disrupting key quaternary Env epitopes; the design 
of TF SHIVs circumvents this non-trivial issue. In addition, our group has generated >20 
TF SHIVs encoding various HIV-1 Env clades, which offers a unique opportunity to test 
these interventions in an NHP model that can recapitulate global HIV-1 diversity. Given 
that TF SHIVs have been recently validated for HIV-1 latency and cure research86, it will 
be important to assess if prophylactic administration of next-generation bNAbs can 1) 





Our group is currently evaluating the efficacy of a CD4 binding site bNAb, 
VRC07, in delaying viral rebound in SHIV.D-infected RM upon ATI. However, more 
studies will be required to validate TF SHIVS for these applications. Further, TF SHIVs 
offer a unique opportunity to dissect the mechanisms responsible for discordant results 
in preclinical studies that utilized SHIVs 162P3 and AD8 to evaluate bNAb therapy and 
clinical trials, where bNAbs did not elicit the same striking effects reported in NHP 
studies, including augmenting CD8 T cell responses and delaying post-ATI viral rebound 
indefinitely56,57. Such studies are likely to assist investigators in developing HIV-1 
therapeutics that are more likely to transition successfully from preclinical to clinical 
development.  
In a previous study, a regimen consisting of a bNAb administered in tandem with 
the latency reversal agent (LRA) GS-9620 significantly delayed rebound in SHIV 162P3-
infected RM following ATI56. LRAS are engineered to reactivate infected cells from 
latency, thus enabling immune targeting and clearance of infected cells. LRAs have 
become a cornerstone of HIV cure strategies; numerous classes of LRAs are currently in 
preclinical and clinical development140. While RM infected with SHIVs AD8 and 162P3 
have demonstrated viremic suppression on cART and viral rebound upon ATI56,57, the 
reservoir biology of these viruses has been incompletely elucidated. The work described 
in Chapter 2 suggests that the viral reservoir dynamics and biology of TF SHIV infection 
is sufficiently similar to HIV-1 infection to enable evaluation of LRAs with or without 
concurrent bNAb administration. 
An additional next step would be to test vaccine candidates using TF SHIVs as a 
challenge virus. One study performed by Felber and colleagues117 demonstrated a  
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significant difference in per exposure SHIV.CH505 acquisition risk in RM co-immunized 
with a DNA vaccine and CH505 Env proteins as described in Chapter 3. Studies by 
other investigators using BG505 SOSIP141 trimers and other promising vaccine 
candidates against autologous TF challenge viruses are ongoing. It will be important to 
repeat these studies using heterologous viruses or a mixture of various TF SHIVs from 
various clades to assess the efficacy of vaccine candidates in a context most similar to 
HIV-1 infection.  
 
Concluding Remarks 
 The studies described here demonstrate for the first time that TF SHIVs are a 
robust NHP model for HIV cure and latency research. Further, this work is the first to 
extensively characterize reservoir biology in SHIV-infected RM both off and on cART in 
the absence of an intervention. In addition, this work provides an experimental 
framework for optimizing SHIVs that persist suboptimally vivo using insights gleaned 
from the theory and results of SHIV serial passage. Taken together, the results 
presented here underscore the promising role of SHIVs, and TF SHIVs in particular, in 
both elucidating mechanisms of HIV pathogenesis, persistence, and reservoir biology 
and evaluating interventions, such as vaccines, prophylactics, and therapeutics, in an 








1. Friedman-Kien A; Laubenstein L; Marmor M; Hymes K; Green J; Ragaz A; 
Gottleib J; Muggia F; Demopoulos R; Weintraub M. Kaposi’s sarcoma and 
Pneumocystis pneumonia among homosexual men--New York City and 
California. MMWR. Morb. Mortal. Wkly. Rep. 30, 305–308 (1981). 
2. Barré-Sinoussi, F. et al. Isolation of a T-lymphotropic retrovirus from a patient at 
risk for acquired immune deficiency syndrome (AIDS). Rev. Investig. Clin. (2004). 
3. Gallo, R. C. et al. Frequent detection and isolation of cytopathic retroviruses 
(HTLV-III) from patients with AIDS and at risk for AIDS. Science (80-. ). (1984) 
doi:10.1126/science.6200936. 
4. UNAIDS. Fact Sheet - World AIDS Day 2018. 
https://www.unaids.org/en/resources/fact-sheet (2018). 
5. Korber, B. Timing the ancestor of the HIV-1 pandemic strains (vol 288, pg 1789, 
2000). Science (80-. ). (2000) doi:10.1126/science.288.5472.1789. 
6. Gao, F. et al. Origin of HIV-1 in the chimpanzee Pan troglodytes troglodytes. 
Nature (1999) doi:10.1038/17130. 
7. Sharp, P. M. & Hahn, B. H. Origins of HIV and the AIDS pandemic. Cold Spring 
Harb. Perspect. Med. (2011) doi:10.1101/cshperspect.a006841. 
8. Clavel, F. et al. Isolation of a new human retrovirus from West African patients 
with AIDS. Science (80-. ). (1986) doi:10.1126/science.2425430. 
9. Hirsch, V. M., Olmsted, R. A., Murphey-Corb, M., Purcell, R. H. & Johnson, P. R. 
An African primate lentivirus (SIVsmclosely related to HIV-2. Nature (1989) 
doi:10.1038/339389a0. 




11. STREBEL K. Virus–host interactions: role of HIV proteins Vif, Tat, and Rev. Aids 
(2003) doi:10.1097/01.aids.0000104337.15729.7e. 
12. Checkley, M. A., Luttge, B. G. & Freed, E. O. HIV-1 envelope glycoprotein 
biosynthesis, trafficking, and incorporation. J. Mol. Biol. 410, 582–608 (2011). 
13. Cheng-Mayer, C., Liu, R., Landau, N. R. & Stamatatos, L. Macrophage tropism of 
human immunodeficiency virus type 1 and utilization of the CC-CKR5 coreceptor. 
J. Virol. (1997). 
14. Hladik, F. & McElrath, M. J. Setting the stage: Host invasion by HIV. Nature 
Reviews Immunology (2008) doi:10.1038/nri2302. 
15. Keele, B. F. et al. Identification and characterization of transmitted and early 
founder virus envelopes in primary HIV-1 infection. Proc. Natl. Acad. Sci. 105, 
7552 LP – 7557 (2008). 
16. Shaw, G. M. & Hunter, E. HIV transmission. Cold Spring Harb. Perspect. Med. 
(2012) doi:10.1101/cshperspect.a006965. 
17. Iyer, S. S. et al. Resistance to type 1 interferons is a major determinant of HIV-1 
transmission fitness. Proc. Natl. Acad. Sci. U. S. A. (2017) 
doi:10.1073/pnas.1620144114. 
18. Coffin, J. & Swanstrom, R. HIV pathogenesis: Dynamics and genetics of viral 
populations and infected cells. Cold Spring Harb. Perspect. Med. (2013) 
doi:10.1101/cshperspect.a012526. 
19. Swanstrom, R. & Coffin, J. HIV-1 pathogenesis: The virus. Cold Spring Harb. 
Perspect. Med. (2012) doi:10.1101/cshperspect.a007443. 
20. Menéndez-Arias, L. Mutation rates and intrinsic fidelity of retroviral reverse 
transcriptases. Viruses (2009) doi:10.3390/v1031137. 
21. Ho, D. D. et al. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 
128 
 
infection. Nature (1995) doi:10.1038/373123a0. 
22. Wei, X. et al. Viral dynamics in human immunodeficiency virus type 1 infection. 
Nature (1995) doi:10.1038/373117a0. 
23. Jones, N. A. et al. Determinants of human immunodeficiency virus type 1 escape 
from the primary CD8+ cytotoxic T lymphocyte response. J. Exp. Med. 200, 1243–
1256 (2004). 
24. Wei, X. et al. Antibody neutralization and escape by HIV-1. Nature 422, 307 
(2003). 
25. Richman, D. D., Wrin, T., Little, S. J. & Petropoulos, C. J. Rapid evolution of the 
neutralizing antibody response to HIV type 1 infection. Proc. Natl. Acad. Sci. 
(2003) doi:10.1073/pnas.0630530100. 
26. Tang, M. W. & Shafer, R. W. HIV-1 antiretroviral resistance: scientific principles 
and clinical applications. Drugs 72, e1–e25 (2012). 
27. Goonetilleke, N. et al. The first T cell response to transmitted/founder virus 
contributes to the control of acute viremia in HIV-1 infection. J. Exp. Med. 206, 
1253 LP – 1272 (2009). 
28. Moore, P. L., Gray, E. S. & Morris, L. Specificity of the autologous neutralizing 
antibody response. Current Opinion in HIV and AIDS (2009) 
doi:10.1097/COH.0b013e32832ea7e8. 
29. Maldarelli, F. et al. HIV Populations Are Large and Accumulate High Genetic 
Diversity in a Nonlinear Fashion. J. Virol. (2013) doi:10.1128/jvi.01225-12. 
30. Buonaguro, L., Tornesello, M. L. & Buonaguro, F. M. Human Immunodeficiency 
Virus Type 1 Subtype Distribution in the Worldwide Epidemic: Pathogenetic and 
Therapeutic Implications. J. Virol. (2007) doi:10.1128/JVI.00872-07. 
31. Taylor, B. S., Sobieszczyk, M. E., McCutchan, F. E. & Hammer, S. M. The 




32. Baalwa, J. et al. Molecular identification, cloning and characterization of 
transmitted/founder HIV-1 subtype A, D and A/D infectious molecular clones. 
Virology (2013) doi:10.1016/j.virol.2012.10.009. 
33. Moore, R. D. & Chaisson, R. E. Natural history of HIV infection in the era of 
combination antiretroviral therapy. AIDS (1999) doi:10.1097/00002030-
199910010-00017. 
34. Andrade, A. et al. Three distinct phases of HIV-1 RNA decay in treatment-naive 
patients receiving raltegravir-based antiretroviral therapy: ACTG A5248. J. Infect. 
Dis. (2013) doi:10.1093/infdis/jit272. 
35. Temesgen, Z. & Siraj, D. S. Raltegravir: first in class HIV integrase inhibitor. Ther. 
Clin. Risk Manag. 4, 493–500 (2008). 
36. DHHS, U. Guidelines for the Use of Antiretroviral Agents in Adults and 
Adolescents with HIV. AIDSinfo (2019). 
37. Samji, H. et al. Closing the gap: Increases in life expectancy among treated HIV-
positive individuals in the United States and Canada. PLoS One (2013) 
doi:10.1371/journal.pone.0081355. 
38. Chun, T.-W., Davey, R. T., Engel, D., Lane, H. C. & Fauci, A. S. Re-emergence of 
HIV after stopping therapy. Nature 401, 874–875 (1999). 
39. Davey, R. T. et al. HIV-1 and T cell dynamics after interruption of highly active 
antiretroviral therapy (HAART) in patients with a history of sustained viral 
suppression. Proc. Natl. Acad. Sci. 96, 15109 LP – 15114 (1999). 
40. Finzi, D. et al. Latent infection of CD4+ T cells provides a mechanism for lifelong 
persistence of HIV-1, even in patients on effective combination therapy. Nat. Med. 
(1999) doi:10.1038/8394. 
41. Dinoso, J. B. et al. Treatment intensification does not reduce residual HIV-1 
130 
 
viremia in patients on highly active antiretroviral therapy. Proc. Natl. Acad. Sci. 
(2009) doi:10.1073/pnas.0903107106. 
42. Kearney, M. F. et al. Lack of Detectable HIV-1 Molecular Evolution during 
Suppressive Antiretroviral Therapy. PLoS Pathog. (2014) 
doi:10.1371/journal.ppat.1004010. 
43. Schrager, L. K. & D’Souza, M. P. Cellular and Anatomical Reservoirs of HIV-1 in 
Patients Receiving Potent Antiretroviral Combination Therapy. JAMA 280, 67–71 
(1998). 
44. Buzon, M. J. et al. Long-Term Antiretroviral Treatment Initiated at Primary HIV-1 
Infection Affects the Size, Composition, and Decay Kinetics of the Reservoir of 
HIV-1-Infected CD4 T Cells. J. Virol. 88, 10056 LP – 10065 (2014). 
45. Maldarelli, F. et al. Specific HIV integration sites are linked to clonal expansion 
and persistence of infected cells. Science (80-. ). (2014) 
doi:10.1126/science.1254194. 
46. Wang, Z. et al. Expanded cellular clones carrying replication-competent HIV-1 
persist, wax, and wane. Proc. Natl. Acad. Sci. (2018) 
doi:10.1073/pnas.1720665115. 
47. Bar, K. J. et al. Effect of HIV Antibody VRC01 on Viral Rebound after Treatment 
Interruption. N. Engl. J. Med. (2016) doi:10.1056/NEJMoa1608243. 
48. Kearney, M. F. et al. Origin of Rebound Plasma HIV Includes Cells with Identical 
Proviruses That Are Transcriptionally Active before Stopping of Antiretroviral 
Therapy. J. Virol. 90, 1369 LP – 1376 (2016). 
49. Bednar, M. M. et al. Diversity and Tropism of HIV-1 Rebound Virus Populations in 
Plasma Level after Treatment Discontinuation. J. Infect. Dis. (2016) 
doi:10.1093/infdis/jiw172. 
50. Rothenberger, M. K. et al. Large number of rebounding/founder HIV variants 
emerge from multifocal infection in lymphatic tissues after treatment interruption. 
131 
 
Proc. Natl. Acad. Sci. (2015) doi:10.1073/pnas.1414926112. 
51. Salantes, D. B. et al. HIV-1 latent reservoir size and diversity are stable following 
brief treatment interruption. J. Clin. Invest. (2018) doi:10.1172/JCI120194. 
52. Montefiori, D. C., Roederer, M., Morris, L. & Seaman, M. S. Neutralization tiers of 
HIV-1. Current Opinion in HIV and AIDS (2018) 
doi:10.1097/COH.0000000000000442. 
53. Cohen, Y. Z. & Caskey, M. Broadly neutralizing antibodies for treatment and 
prevention of HIV-1 infection. Curr. Opin. HIV AIDS 13, 366–373 (2018). 
54. Nishimura, Y. & Martin, M. A. Of Mice, Macaques, and Men: Broadly Neutralizing 
Antibody Immunotherapy for HIV-1. Cell Host and Microbe (2017) 
doi:10.1016/j.chom.2017.07.010. 
55. Nishimura, Y. et al. Early antibody therapy can induce long-lasting immunity to 
SHIV. Nature (2017) doi:10.1038/nature21435. 
56. Borducchi, E. N. et al. Antibody and TLR7 agonist delay viral rebound in SHIV-
infected monkeys. Nature (2018) doi:10.1038/s41586-018-0600-6. 
57. Shingai, M. et al. Antibody-mediated immunotherapy of macaques chronically 
infected with SHIV suppresses viraemia. Nature (2013) doi:10.1038/nature12746. 
58. Scheid, J. F. et al. HIV-1 antibody 3BNC117 suppresses viral rebound in humans 
during treatment interruption. Nature (2016) doi:10.1038/nature18929. 
59. Gruell, H. & Klein, F. Antibody-mediated prevention and treatment of HIV-1 
infection. Retrovirology 15, 73 (2018). 
60. Kumar, N., Chahroudi, A. & Silvestri, G. Animal models to achieve an HIV cure. 
Curr. Opin. HIV AIDS 11, 432–441 (2016). 
61. Garcia-Tellez, T. et al. Non-human primates in HIV research: Achievements, limits 
and alternatives. Infect. Genet. Evol. (2016) doi:10.1016/j.meegid.2016.07.012. 
132 
 
62. Li, Q. et al. Peak SIV replication in resting memory CD4 + T cells depletes gut 
lamina propria CD4 + T cells. Nature (2005) doi:10.1038/nature03513. 
63. Schmitz, J. E. & Korioth-Schmitz, B. Immunopathogenesis of simian 
immunodeficiency virus infection in nonhuman primates. Curr. Opin. HIV AIDS 8, 
273–279 (2013). 
64. Mavigner, M. et al. Simian Immunodeficiency Virus Persistence in Cellular and 
Anatomic Reservoirs in Antiretroviral Therapy-Suppressed Infant Rhesus 
Macaques. J. Virol. (2018) doi:10.1128/jvi.00562-18. 
65. Parker, R. A., Regan, M. M. & Reimann, K. A. Variability of viral load in plasma of 
rhesus monkeys inoculated with simian immunodeficiency virus or simian-human 
immunodeficiency virus: implications for using nonhuman primate AIDS models to 
test vaccines and therapeutics. J. Virol. 75, 11234–11238 (2001). 
66. Foley B, Leitner T, Apetrei C, Hahn B, Mizrachi I, Mullins J, Rambaut A, Wolinsky 
S, and Korber B. Published by Theoretical Biology and Biophysics Group, Los 
Alamos National Laboratory, N. HIV Sequence Compendium 2018. LA-UR 18-
25673. 
67. Reimann, K. A. et al. A chimeric simian/human immunodeficiency virus 
expressing a primary patient human immunodeficiency virus type 1 isolate env 
causes an AIDS-like disease after in vivo passage in rhesus monkeys. J. Virol. 70, 
6922 LP – 6928 (1996). 
68. Etemad-Moghadam, B. et al. Envelope glycoprotein determinants of increased 
fusogenicity in a pathogenic simian-human immunodeficiency virus (SHIV-KB9) 
passaged in vivo. J. Virol. 74, 4433–4440 (2000). 
69. Regoes, R. R. & Bonhoeffer, S. The HIV coreceptor switch: A population 
dynamical perspective. Trends in Microbiology (2005) 
doi:10.1016/j.tim.2005.04.005. 
70. Feinberg, M. B. & Moore, J. P. AIDS vaccine models: Challenging challenge 
133 
 
viruses. Nat. Med. 8, 207–210 (2002). 
71. Harouse, J. M. et al. Mucosal Transmission and Induction of Simian AIDS by 
CCR5-Specific Simian/Human Immunodeficiency Virus SHIVSF162P3. J. Virol. 
75, 1990–1995 (2001). 
72. Krachmarov, C. P. et al. Factors Determining the Breadth and Potency of 
Neutralization by V3-Specific Human Monoclonal Antibodies Derived from 
Subjects Infected with Clade A or Clade B Strains of Human Immunodeficiency 
Virus Type 1. J. Virol. (2006) doi:10.1128/jvi.02619-05. 
73. Tartaglia, L. J. et al. Differential Outcomes following Optimization of Simian-
Human Immunodeficiency Viruses from Clades AE, B, and C. J. Virol. 94, 
e01860-19 (2020). 
74. Wang, W. et al. Comparison of viral burden and disease progression in Chinese-
origin rhesus macaques infected with common experimentally applied chimeric 
virus: SHIV-1157ipd3N4, SHIV-162P3, or SHIV-KB9. J. Med. Primatol. (2014) 
doi:10.1111/jmp.12117. 
75. Song, R. J. et al. Molecularly Cloned SHIV-1157ipd3N4: a Highly Replication- 
Competent, Mucosally Transmissible R5 Simian-Human Immunodeficiency Virus 
Encoding HIV Clade C env. J. Virol. (2006) doi:10.1128/jvi.00558-06. 
76. Nishimura, Y. et al. Generation of the Pathogenic R5-Tropic Simian/Human 
Immunodeficiency Virus SHIVAD8 by Serial Passaging in Rhesus Macaques. J. 
Virol. (2010) doi:10.1128/jvi.02279-09. 
77. Shingai, M. et al. Most rhesus macaques infected with the CCR5-tropic SHIVAD8 
generate cross-reactive antibodies that neutralize multiple HIV-1 strains. Proc. 
Natl. Acad. Sci. U. S. A. 109, 19769–19774 (2012). 
78. Gautam, R. et al. Pathogenicity and Mucosal Transmissibility of the R5-Tropic 
Simian/Human Immunodeficiency Virus SHIV AD8 in Rhesus Macaques: 
Implications for Use in Vaccine Studies. J. Virol. 86, 8516 LP – 8526 (2012). 
134 
 
79. Barouch, D. H. et al. Therapeutic efficacy of potent neutralizing HIV-1-specific 
monoclonal antibodies in SHIV-infected rhesus monkeys. Nature (2013) 
doi:10.1038/nature12744. 
80. Parrish, N. F. et al. Phenotypic properties of transmitted founder HIV-1. Proc. Natl. 
Acad. Sci. 110, 6626 LP – 6633 (2013). 
81. Salazar-Gonzalez, J. F. et al. Genetic identity, biological phenotype, and 
evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 
infection. J. Exp. Med. (2009) doi:10.1084/jem.20090378. 
82. Albert, J. et al. Rapid development of isolate-specific neutralizing antibodies after 
primary HIV-1 infection and consequent emergence of virus variants which resist 
neutralization by autologous sera. AIDS (1990) doi:10.1097/00002030-
199002000-00002. 
83. Del Prete, G. Q. et al. Selection of unadapted, pathogenic SHIVs encoding newly 
transmitted HIV-1 envelope proteins. Cell Host Microbe (2014) 
doi:10.1016/j.chom.2014.08.003. 
84. Li, H. et al. Envelope residue 375 substitutions in simian–human 
immunodeficiency viruses enhance CD4 binding and replication in rhesus 
macaques. Proc. Natl. Acad. Sci. (2016) doi:10.1073/pnas.1606636113. 
85. Bar, K. J. et al. SHIV.CH505 infection of rhesus macaques results in persistent 
viral replication and induces intestinal immunopathology. J. Virol. JVI.00372-19 
(2019) doi:10.1128/JVI.00372-19. 
86. Bauer, A. M. et al. Novel Transmitted/Founder Simian-Human Immunodeficiency 
Viruses for Human Immunodeficiency Virus Latency and Cure Research. J. Virol. 
94, e01659-19 (2020). 
87. Shaw, G. M. Recapitulation of HIV-1 Envelope-Antibody Coevolution in Rhesus 
Macaques Leading to Strain-Specific and Broadly Neutralizing Antibodies. in 
Progress and Pathways Toward an Effective HIV Vaccine (2018). 
135 
 
88. Nelson, A. N. et al. Simian-Human Immunodeficiency Virus SHIV.CH505-Infected 
Infant and Adult Rhesus Macaques Exhibit Similar Env-Specific Antibody Kinetics, 
despite Distinct T-Follicular Helper and Germinal Center B Cell Landscapes. J. 
Virol. (2019) doi:10.1128/jvi.00168-19. 
89. Goswami, R. et al. Analytical treatment interruption after short-term antiretroviral 
therapy in a postnatally simian-human immunodeficiency virus-infected infant 
rhesus macaque model. MBio (2019) doi:10.1128/mBio.01971-19. 
90. Monjure, C. J. et al. Optimization of PCR for quantification of simian 
immunodeficiency virus genomic RNA in plasma of rhesus macaques (Macaca 
mulatta) using armored RNA. J. Med. Primatol. (2014) doi:10.1111/jmp.12088. 
91. Sarzotti-Kelsoe, M. et al. Optimization and validation of the TZM-bl assay for 
standardized assessments of neutralizing antibodies against HIV-1. J. Immunol. 
Methods 409, 131–146 (2014). 
92. Rawson, J. M. O., Landman, S. R., Reilly, C. S. & Mansky, L. M. HIV-1 and HIV-2 
exhibit similar mutation frequencies and spectra in the absence of G-to-A 
hypermutation. Retrovirology (2015) doi:10.1186/s12977-015-0180-6. 
93. Menéndez-Arias, L., Rawson, J. M. O., Landman, S. R., Reilly, C. S. & Mansky, L. 
M. Mutation rates and intrinsic fidelity of retroviral reverse transcriptases. Viruses 
(2015) doi:10.3390/v1031137. 
94. Ribeiro, R. M. et al. Estimation of the Initial Viral Growth Rate and Basic 
Reproductive Number during Acute HIV-1 Infection. J. Virol. (2010) 
doi:10.1128/jvi.00127-10. 
95. Barditch-Crovo, P. et al. Phase I/II Trial of the Pharmacokinetics, Safety, and 
Antiretroviral Activity of Tenofovir Disoproxil Fumarate in Human 
Immunodeficiency Virus-Infected Adults. Antimicrob. Agents Chemother. 45, 2733 
LP – 2739 (2001). 
96. Van Rompay, K. K. et al. 9-[2-(Phosphonomethoxy)propyl]adenine therapy of 
136 
 
established simian immunodeficiency virus infection in infant rhesus macaques. 
Antimicrob. Agents Chemother. 40, 2586–2591 (1996). 
97. Cressey, T. R. et al. A randomized clinical pharmacokinetic trial of Tenofovir in 
blood, plasma and urine in adults with perfect, moderate and low PrEP 
adherence: the TARGET study. BMC Infect. Dis. 17, 496 (2017). 
98. Martin, A. et al. Pharmacokinetic profile of raltegravir, elvitegravir and dolutegravir 
in plasma and mucosal secretions in rhesus macaques. J. Antimicrob. 
Chemother. 70, 1473–1481 (2015). 
99. Rambaut, A. (University of E. FigTree v1.4.4. 
http://tree.bio.ed.ac.uk/software/figtree/ (2018). 
100. Deng, W. et al. DIVEIN: a web server to analyze phylogenies, sequence 
divergence, diversity, and informative sites. Biotechniques 48, 405–408 (2010). 
101. Bonsignori, M. et al. Staged induction of HIV-1 glycan-dependent broadly 
neutralizing antibodies. Sci. Transl. Med. (2017) 
doi:10.1126/scitranslmed.aai7514. 
102. Hatziioannou, T. & Evans, D. T. Animal models for HIV/AIDS research. Nat. Rev. 
Microbiol. 10, 852 (2012). 
103. Ananworanich, J. et al. Viral kinetics in untreated versus treated acute HIV 
infection in prospective cohort studies in Thailand. J. Int. AIDS Soc. 20, 21652 
(2017). 
104. Ananworanich, J. et al. HIV DNA Set Point is Rapidly Established in Acute HIV 
Infection and Dramatically Reduced by Early ART. EBioMedicine 11, 68–72 
(2016). 
105. Ten Haaft, P. et al. Comparison of early plasma RNA loads in different macaque 
species and the impact of different routes of exposure on SIV/SHIV infection. J. 
Med. Primatol. (2001) doi:10.1034/j.1600-0684.2001.d01-54.x. 
137 
 
106. Pasternak, A. O., Lukashov, V. V & Berkhout, B. Cell-associated HIV RNA: a 
dynamic biomarker of viral persistence. Retrovirology 10, 41 (2013). 
107. Furtado, M. R. et al. Persistence of HIV-1 Transcription in Peripheral-Blood 
Mononuclear Cells in Patients Receiving Potent Antiretroviral Therapy. N. Engl. J. 
Med. 340, 1614–1622 (1999). 
108. Avettand-Fènoël, V. et al. Total HIV-1 DNA, a Marker of Viral Reservoir Dynamics 
with Clinical Implications. Clin. Microbiol. Rev. 29, 859 LP – 880 (2016). 
109. Chomont, N. et al. HIV reservoir size and persistence are driven by T cell survival 
and homeostatic proliferation. Nat. Med. 15, 893–900 (2009). 
110. Schmitz, J. E. et al. Control of viremia in simian immunodeficiency virus infection 
by CD8+ lymphocytes. Science (80-. ). (1999) doi:10.1126/science.283.5403.857. 
111. Borrow, P., Lewicki, H., Hahn, B. H., Shaw, G. M. & Oldstone, M. B. Virus-specific 
CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary 
human immunodeficiency virus type 1 infection. J. Virol. (1994). 
112. Veazey, R. S. et al. Gastrointestinal Tract as a Major Site of CD4 T Cell Depletion 
and Viral Replication in SIV Infection. Science (80-. ). 280, 427 LP – 431 (1998). 
113. Pantaleo, G. et al. Lymphoid organs function as major reservoirs for human 
immunodeficiency virus. Proc. Natl. Acad. Sci. (2006) 
doi:10.1073/pnas.88.21.9838. 
114. Cheng‐Mayer, C. & Levy, J. A. Distinct biological and serological properties of 
human immunodeficiency viruses from the brain. Ann. Neurol. (1988) 
doi:10.1002/ana.410230716. 
115. Gendelman He et al. Efficient isolation and propagation of human 
immunodeficiency virus on recombinant colony-stimulating factor 1-treated 
monocytes. J. Exp. Med. (1988). 
116. Humes, D., Emery, S., Laws, E. & Overbaugh, J. A Species-Specific Amino Acid 
138 
 
Difference in the Macaque CD4 Receptor Restricts Replication by Global 
Circulating HIV-1 Variants Representing Viruses from Recent Infection. J. Virol. 
86, 12472 LP – 12483 (2012). 
117. Felber, B. K. et al. Co-immunization of DNA and Protein in the Same Anatomical 
Sites Induces Superior  Protective Immune Responses against SHIV Challenge. 
Cell Rep. 31, 107624 (2020). 
118. Liao, H.-X. et al. Co-evolution of a broadly neutralizing HIV-1 antibody and 
founder virus. Nature 496, 469–476 (2013). 
119. Li H, Williams WB, Chug H, Roark R, Bonsignori M, Lee FH, Wang S, Hraber P, 
Giorgi E, Haynes BF, Korber B, Harrison SC, Hahn BH, S. G. Recapitulation of 
HIV Envelope-Antibody Coevolution in SHIV Infected Rhesus Macaques Leading 
to Neutralization Breadth. in Keystone Symposia, HIV Vaccines (X7) (2019). 
120. Hansen, S. G. et al. Immune clearance of highly pathogenic SIV infection. Nature 
(2013) doi:10.1038/nature12519. 
121. Fennessey, C. M. et al. Genetically-barcoded SIV facilitates enumeration of 
rebound variants and estimation of reactivation rates in nonhuman primates 
following interruption of suppressive antiretroviral therapy. PLoS Pathog. 13, 
e1006359–e1006359 (2017). 
122. Shaik, M. M. et al. Structural basis of coreceptor recognition by HIV-1 envelope 
spike. Nature 565, 318–323 (2019). 
123. Kumar, R. et al. Characterization of a stable HIV-1 B/C recombinant, soluble, and 
trimeric envelope glycoprotein (Env) highly resistant to CD4-induced 
conformational changes. J. Biol. Chem.  292, 15849–15858 (2017). 
124. Heredia, J. D., Park, J., Choi, H., Gill, K. S. & Procko, E. Conformational 
Engineering of HIV-1 Env Based on Mutational Tolerance in the CD4 and PG16 
Bound States. J. Virol. (2019) doi:10.1128/jvi.00219-19. 
125. Wibmer, C. K. et al. Viral escape from HIV-1 neutralizing antibodies drives 
139 
 
increased plasma neutralization breadth through sequential recognition of multiple 
epitopes and immunotypes. PLoS Pathog. 9, e1003738–e1003738 (2013). 
126. Li, Y. et al. Critical amino acids within the human immunodeficiency virus type 1 
envelope glycoprotein V4 N- and C-terminals contribute to virus entry. PLoS One 
(2014) doi:10.1371/journal.pone.0086083. 
127. Yuan, T., Li, J. & Zhang, M. Y. HIV-1 Envelope Glycoprotein Variable Loops Are 
Indispensable for Envelope Structural Integrity and Virus Entry. PLoS One (2013) 
doi:10.1371/journal.pone.0069789. 
128. Robb, M. L. et al. Prospective Study of Acute HIV-1 Infection in Adults in East 
Africa and Thailand. N. Engl. J. Med. 374, 2120–2130 (2016). 
129. Davis, K. L. et al. Human Immunodeficiency Virus Type 2 (HIV-2)/HIV-1 Envelope 
Chimeras Detect High Titers of Broadly Reactive HIV-1 V3-Specific Antibodies in 
Human Plasma. J. Virol. 83, 1240 LP – 1259 (2009). 
130. Davis, K. L. et al. High titer HIV-1 V3-specific antibodies with broad reactivity but 
low neutralizing potency in acute infection and following vaccination. Virology 387, 
414–426 (2009). 
131. LaBranche, C. C. et al. HIV-1 envelope glycan modifications that permit 
neutralization by germline-reverted VRC01-class broadly neutralizing antibodies. 
PLoS Pathog. (2018) doi:10.1371/journal.ppat.1007431. 
132. Thali, M. et al. Characterization of conserved human immunodeficiency virus type 
1 gp120 neutralization epitopes exposed upon gp120-CD4 binding. J. Virol. 67, 
3978–3988 (1993). 
133. Martin, K. A. et al. CD4-Independent Binding of SIV gp120 to Rhesus CCR5. 
Science (80-. ). 278, 1470 LP – 1473 (1997). 
134. Voss, J. E. et al. Elicitation of Neutralizing Antibodies Targeting the V2 Apex of 




135. Cale, E. M. et al. Virus-like Particles Identify an HIV V1V2 Apex-Binding 
Neutralizing Antibody that Lacks a Protruding Loop. Immunity 46, 777-791.e10 
(2017). 
136. Del Prete, G. Q. et al. A single gp120 residue can affect HIV-1 tropism in 
macaques. PLoS Pathog. 13, e1006572–e1006572 (2017). 
137. Bruner, K. M. et al. A quantitative approach for measuring the reservoir of latent 
HIV-1 proviruses. Nature 566, 120–125 (2019). 
138. Veazey, R. S. et al. Protection of rhesus macaques from vaginal infection by 
vaginally delivered maraviroc, an inhibitor of HIV-1 entry via the CCR5 co-
receptor. J. Infect. Dis. 202, 739–744 (2010). 
139. Boyd, D. F. et al. Mutations in HIV-1 Envelope That Enhance Entry with the 
Macaque CD4 Receptor Alter Antibody Recognition by Disrupting Quaternary 
Interactions within the Trimer. J. Virol. (2015) doi:10.1128/jvi.02680-14. 
140. Spivak, A. M. & Planelles, V. Novel Latency Reversal Agents for HIV-1 Cure. 
Annu. Rev. Med. (2018) doi:10.1146/annurev-med-052716-031710. 
141. Sanders, R. W. et al. A next-generation cleaved, soluble HIV-1 Env trimer, BG505 
SOSIP.664 gp140,  expresses multiple epitopes for broadly neutralizing but not 
non-neutralizing antibodies. PLoS Pathog. 9, e1003618 (2013). 
 
 
